var title_f22_28_22976="Physiology normal micturition";
var content_f22_28_22976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Diagram showing neural circuits controlling continence and micturition",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 456px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Urine storage reflexes. During the storage of urine, distention of the bladder produces low level vesical afferent firing, which in turn stimulates (1) the sympathetic outflow to the bladder outlet (base and urethra) and (2) pudendal outflow to the external urethral sphincter. These responses occur by spinal reflex pathways and represent \"guarding reflexes,\" which promote continence. Sympathetic firing also inhibits detrusor muscle and modulates transmission in bladder ganglia. A region in the rostral pons (the pontine storage center, or \"L\" region) increases external urethral sphincter activity. (B) Voiding reflexes. During elimination of urine, intense bladder afferent firing activates spinobulbospinal reflex pathways passing through the pontine micturition center, which stimulate the parasympathetic outflow to the bladder and internal sphincter smooth muscle and inhibit the sympathetic and pudendal outflow to the urethral outlet. Ascending afferent input from the spinal cord may pass through relay neurons in the periaqueductal gray (PAG) before reaching the pontine micturition center.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Abrams, P, Cardozo, L, Wein, A, eds. Incontinence: 2nd ed International Consultation on Incontinence, Health Publications Ltd. 2002. p.88. Copyright &copy; Health Publications.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22976=[""].join("\n");
var outline_f22_28_22976=null;
var title_f22_28_22977="Adrenal adenoma hypodense";
var content_f22_28_22977=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypodense adrenal adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abdominal CT showing a 1.5-cm round hypodense left adrenal cortical adenoma (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William F Young, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22977=[""].join("\n");
var outline_f22_28_22977=null;
var title_f22_28_22978="Patient information: Glioblastoma (The Basics)";
var content_f22_28_22978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/48/9986\">",
"         Patient information: Brain cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?15/51/16179\">",
"         Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/52/8004\">",
"         Patient information: High-grade glioma in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/27/34229\">",
"         Patient information: Seizures in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Glioblastoma (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/glioblastoma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13776152\">",
"      <span class=\"h1\">",
"       What is glioblastoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Glioblastoma (also called &ldquo;glioblastoma multiforme&rdquo; or &ldquo;GBM&rdquo;) is a fast growing type of brain cancer. Brain cancer happens when normal cells in the brain change into abnormal cells and grow out of control. &nbsp;",
"     </p>",
"     <p>",
"      Brain cancers can be named after the type of cell they start from. GBM starts in the &ldquo;glial&rdquo; cells of the brain. Glial cells go between and around the brain&rsquo;s nerve cells. &nbsp;",
"     </p>",
"     <p>",
"      As GBM grows, it can spread into healthy parts of the brain. It can also cause brain swelling. Both these things can cause symptoms. &nbsp;",
"     </p>",
"     <p>",
"      Getting radiation treatment earlier in life can raise a person&rsquo;s risk for GBM.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13776169\">",
"      <span class=\"h1\">",
"       What are the symptoms of glioblastoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Headaches",
"       </li>",
"       <li>",
"        Seizures",
"       </li>",
"       <li>",
"        Memory or thinking problems",
"       </li>",
"       <li>",
"        Muscle weakness",
"       </li>",
"       <li>",
"        Vision changes, such as double vision or vision loss",
"       </li>",
"       <li>",
"        Language problems, such as trouble finding the right word for something",
"       </li>",
"       <li>",
"        Personality changes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other conditions can also cause these symptoms. But you should tell your doctor or nurse if any of these things happen. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13776184\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes.",
"      <strong>",
"      </strong>",
"      The doctor will do an exam and order imaging tests, such as an MRI or a CT scan. Imaging tests create pictures of your brain. The pictures can show GBM or other abnormal growths. They can also show other kinds of changes that might be causing symptoms.",
"     </p>",
"     <p>",
"      To tell if a person has GBM, doctors need to look at a sample of the tumor under the microscope. If the doctor thinks a brain tumor might be GBM, he or she usually does surgery to take out as much of the tumor as possible. Then, another doctor looks at a small sample of tumor tissue under a microscope. The sample can show if the tumor is GBM, a different type of brain tumor, or a sign of another brain condition.",
"     </p>",
"     <p>",
"      Some people with GBM do not have surgery to remove the tumor. If the doctor does not do surgery, he or she might use a needle to take a small sample from the tumor. This can be done if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The GBM is in a part of the brain where surgery is too risky.",
"       </li>",
"       <li>",
"        The GBM is too large for surgery to help. &nbsp;",
"       </li>",
"       <li>",
"        The person is too sick for surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13776201\">",
"      <span class=\"h1\">",
"       How is glioblastoma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for GBM usually includes:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery&nbsp;&ndash; During surgery, doctors take out as much of the GBM as they can. This can help with symptoms and help people live longer. But surgery can hurt healthy areas of the brain. During surgery, doctors take out what they can without hurting healthy areas. &nbsp;",
"       </li>",
"       <li>",
"        Radiation therapy&nbsp;&ndash; Radiation kills some of the cancer cells. Most people with GBM have radiation therapy after surgery.",
"       </li>",
"       <li>",
"        Chemotherapy&nbsp;&ndash; &ldquo;Chemotherapy&rdquo; is the term doctors use for medicines that kill cancer cells. Most people with GBM have chemotherapy after surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After surgery, doctors usually give radiation therapy and chemotherapy at the same time.",
"     </p>",
"     <p>",
"      <br/>",
"      GBM can cause seizures and brain swelling. Doctors can give medicines or do surgery to treat these symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13776216\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will have regular checkups to see if the GBM comes back. This includes having imaging tests (usually MRIs) of the brain.",
"     </p>",
"     <p>",
"      You should watch for the common symptoms of GBM, and any other symptoms you had before your doctor found the GBM. Having symptoms could mean the GBM has come back. Tell your doctor or nurse about any symptoms you have.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13776233\">",
"      <span class=\"h1\">",
"       What if the glioblastoma comes back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In most people, GBM comes back after treatment. If an imaging test shows changes in the brain after treatment, the changes could be caused by the GBM coming back, or they could be changes that happen in response to treatment. It can be hard to tell the difference between these changes. The doctor might do repeat imaging tests to see if the changes are cancer.",
"     </p>",
"     <p>",
"      If GBM comes back or spreads, you might have more surgery, chemotherapy, or radiation. Your doctor or nurse will talk with you about the best treatment for you. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13776250\">",
"      <span class=\"h1\">",
"       Should I be in a clinical trial?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have GBM, you might want to be in a &ldquo;clinical trial.&rdquo; A clinical trial is a research study that tests new medicines and treatments to see how well they work.",
"     </p>",
"     <p>",
"      Being in a clinical trial might or might not change your symptoms or help you live longer. But it can give doctors more information about GBM and how to treat it. Information from the study can help them create new and better medicines and treatments.",
"     </p>",
"     <p>",
"      There are clinical trials for GBM all over the world. To find out more about being in a clinical trial, talk with your doctor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13776267\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should follow your doctor&rsquo;s instructions about checkups and tests. Talk to your doctor about any problems during treatment.",
"     </p>",
"     <p>",
"      If GBM comes back, tell your doctors and nurses how you feel about the different treatments. Any time your doctor talks with you about a new treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        What are the benefits of this treatment? Will it help me live longer? Will it reduce my symptoms or stop them?",
"       </li>",
"       <li>",
"        What bad things could happen if I have this treatment?",
"       </li>",
"       <li>",
"        Do I have other choices besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13776284\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/48/9986?source=see_link\">",
"       Patient information: Brain cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/52/8004?source=see_link\">",
"       Patient information: High-grade glioma in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=see_link\">",
"       Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=see_link\">",
"       Patient information: Seizures in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/28/22978?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82941 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.244-3BAB8F1ACB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22978=[""].join("\n");
var outline_f22_28_22978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13776152\">",
"      What is glioblastoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13776169\">",
"      What are the symptoms of glioblastoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13776184\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13776201\">",
"      How is glioblastoma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13776216\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13776233\">",
"      What if the glioblastoma comes back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13776250\">",
"      Should I be in a clinical trial?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13776267\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13776284\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/48/9986?source=related_link\">",
"      Patient information: Brain cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/52/8004?source=related_link\">",
"      Patient information: High-grade glioma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_28_22979="Condyloma lata";
var content_f22_28_22979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Condyloma lata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flat condyloma lata lesions which are moist in a woman with secondary syphilis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David H Martin and Tomasz F Mroczkowski. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22979=[""].join("\n");
var outline_f22_28_22979=null;
var title_f22_28_22980="Langerhans histiocytosis PA I";
var content_f22_28_22980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph demonstrates the classic features of profuse ill-defined nodules, reticulondoular opacities, cysts, and costophrenic angle sparing in pulmonary LCH. There is a mild reduction in lung volumes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22980=[""].join("\n");
var outline_f22_28_22980=null;
var title_f22_28_22981="Chlorpheniramine, pseudoephedrine, and dextromethorphan: Patient drug information";
var content_f22_28_22981=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine, pseudoephedrine, and dextromethorphan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/37/19030?source=see_link\">",
"     see \"Chlorpheniramine, pseudoephedrine, and dextromethorphan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dicel&reg; DM Chewables [OTC];",
"     </li>",
"     <li>",
"      Kidkare Children's Cough/Cold [OTC];",
"     </li>",
"     <li>",
"      M-END DM [OTC];",
"     </li>",
"     <li>",
"      Maxichlor PSE DM [OTC] [DSC];",
"     </li>",
"     <li>",
"      Neutrahist PDX [OTC];",
"     </li>",
"     <li>",
"      Pedia Relief&trade; Cough-Cold [OTC];",
"     </li>",
"     <li>",
"      Pediatric Cough &amp; Cold [OTC];",
"     </li>",
"     <li>",
"      Rescon DM [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701784",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chlorpheniramine, pseudoephedrine, dextromethorphan, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11328 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22981=[""].join("\n");
var outline_f22_28_22981=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150449\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024065\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024067\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024066\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024071\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024072\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024074\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024069\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024070\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024075\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024076\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/37/19030?source=related_link\">",
"      Chlorpheniramine, pseudoephedrine, and dextromethorphan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_28_22982="Hydrochlorothiazide and spironolactone: Pediatric drug information";
var content_f22_28_22982=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrochlorothiazide and spironolactone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/58/22438?source=see_link\">",
"    see \"Hydrochlorothiazide and spironolactone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/5/25685?source=see_link\">",
"    see \"Hydrochlorothiazide and spironolactone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aldactazide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aldactazide 25&reg;;",
"     </li>",
"     <li>",
"      Aldactazide 50&reg;;",
"     </li>",
"     <li>",
"      Novo-Spirozine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent, Combination",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Combination",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/58/22438?source=see_link\">",
"      see \"Hydrochlorothiazide and spironolactone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Product is a fixed combination of equal",
"     <b>",
"      mg proportions of components",
"     </b>",
"     ; the following dosage represents mg of each component  (spironolactone and hydrochlorothiazide).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Hypertension,  diuresis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: Limited data available: Oral: 1-3 mg/kg/day in divided doses once or twice daily (Engelhardt, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children and Adolescents: Oral: Initial: 1 mg/kg/day in divided doses once or twice daily, may titrate up to maximum daily dose: 3-3.3 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     or 100 mg/",
"     <b>",
"      day",
"     </b>",
"     of spironolactone (NHBPEP, 2004; NHLBI, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Hypertension, edema:",
"     </b>",
"     Oral: 12.5-50 mg/day; manufacturer labeling states hydrochlorothiazide maximum 200 mg/day; however, usual dose in JNC-7 is 12.5-50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults: Efficacy of hydrochlorothiazide is limited in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute; contraindicated in patients with anuria",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Hydrochlorothiazide 25 mg and spironolactone 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Aldactazide&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     25/25: Hydrochlorothiazide 25 mg and spironolactone 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     50/50: Hydrochlorothiazide 50 mg and spironolactone 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer in the morning; administer the last dose of multiple doses before 6 PM unless instructed otherwise",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F15120918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store below 25&deg;C (77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of edematous conditions associated with heart failure, cirrhosis of the liver, and nephrotic syndrome when other diuretics are inappropriate (eg, hypokalemia) or lacked adequate response (FDA approved in adults); treatment of essential hypertension (FDA approved in adults).",
"     <b>",
"      Note:",
"     </b>",
"     Use in pregnancy should be reserved for those cases causing extreme discomfort and unrelieved by rest; should not be routinely used during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F179747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aldactazide&reg; may be confused with Aldactone&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F179745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydrochlorothiazide, spironolactone, or any component; cross-sensitivity with other thiazides or sulfonamides; anuria, hyperkalemia, acute or significant  renal impairment, acute or severe hepatic failure",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5729342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hyperkalemia  may occur with spironolactone; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Concomitant administration of potassium-sparing diuretics (eg, amiloride and triamterene) and ACE inhibitors or NSAIDs has been associated with severe hyperkalemia; may cause transient elevation of BUN, possibly due to a concentration effect; sustained elevations should be evaluated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides. Use with caution in patients with prediabetes or diabetes mellitus; may alter glucose control. Use with caution in patients having a history of gout; thiazide diuretics may cause hyperuricemia and in certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated. Use with caution in patients with hypercalcemia or parathyroid disease; thiazide diuretics may decrease renal calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This fixed combination is not indicated for initial therapy of hypertension or edema",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; therapy requires titration to the individual patient; if dosage so determined represents this fixed combination, its use may be more convenient; use with caution in impaired hepatic function, electrolyte changes may precipitate hepatic encephalopathy; spironolactone has been shown to be a tumorigen in chronic toxicity animal studies",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma. Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling; however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause  acute transient myopia and acute angle-closure glaucoma with potential for loss of vision; typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy. May cause SLE exacerbation or activation. Photosensitization may occur; patients should be counseled. May cause gynecomastia; development associated with dose and duration of therapy; typically is reversible upon discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: Spironolactone may diminish the therapeutic effect of Abiraterone Acetate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Spironolactone may diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Spironolactone may increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasing Digoxin concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drospirenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: Spironolactone may diminish the therapeutic effect of Mitotane.  Management: Consideration should be given to discontinuing spironolactone prior to initiating mitotane in order to eliminate the risk of therapeutic failure of the mitotane.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Spironolactone may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrofurantoin: May enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1059306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid food with high potassium content, natural licorice (causes sodium and water retention and increases potassium loss), and salt substitutes",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F179723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, BUN, creatinine, blood pressure, fluid balance, body weight",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15120919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F15121123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/5/25685?source=see_link\">",
"      see \"Hydrochlorothiazide and spironolactone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10950999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An oral suspension containing hydrochlorothiazide 5 mg and spironolactone 5 mg per mL may be made with tablets. Crush twenty-four 25 mg hydrochlorothiazide and twenty-four 25 mg spironolactone tablets and reduce to a fine powder. Add small portions of a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; and mix to a uniform paste; mix while adding the vehicle in equal proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 120 mL. Label \"shake well\". Stable 60 days under refrigeration or at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV and Erickson MA, \"Stability of Extemporaneously Prepared Pediatric Formulations Using Ora-Plus With Ora-Sweet and Ora-Sweet SF &minus; Part II,\"",
"     <i>",
"      Secundum Artem",
"     </i>",
"     , Volume 6 (1). Available at: www.paddocklabs.com.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, \"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22982/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engelhardt B, Blalock WA, DonLevy S, et al, \"Effect of Spironolactone-Hydrochlorothiazide on Lung Function in Infants With Chronic Bronchopulmonary Dysplasia,\"",
"      <i>",
"       J Pediatrics",
"      </i>",
"      , 1989, 114:619-24.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, \"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,\"",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , 2011, National Institutes of Health. Available at file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf. Date accessed: June 11, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl 4th Report):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22982/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13358 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F1B7A60FFB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22982=[""].join("\n");
var outline_f22_28_22982=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708903\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179727\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179728\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059299\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059293\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179715\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179703\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059302\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15120918\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059301\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179747\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179745\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059305\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5729342\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059292\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299456\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179710\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059306\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179711\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179723\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059298\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15120919\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15121123\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10950999\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13358\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13358|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/58/22438?source=related_link\">",
"      Hydrochlorothiazide and spironolactone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/5/25685?source=related_link\">",
"      Hydrochlorothiazide and spironolactone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_28_22983="Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?";
var content_f22_28_22983=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/28/22983/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/28/22983/contributors\">",
"     Stuart Sherman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/28/22983/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/28/22983/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/28/22983/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/28/22983/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/28/22983/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic placement of polyethylene stents is a well-established therapy for treating a variety of benign and malignant biliary tract diseases. Although still in their infancy, application of similar techniques in the pancreas is emerging. Pancreatic duct stents have been placed to bridge dominant strictures, bypass obstructing pancreatic duct stones, drain pseudocysts, seal duct disruptions, treat symptomatic minor (ie, pancreas divisum)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    major (ie, sphincter of Oddi dysfunction) sphincter stenosis, prevent procedure-induced pancreatitis, and serve as a guide for sphincterotomy (",
"    <a class=\"graphic graphic_table graphicRef51003 \" href=\"UTD.htm?19/17/19739\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic review will focus on the indications and efficacy of placing a pancreatic stent to prevent post-ERCP pancreatitis. An overview of pancreatic stenting and its complications is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=see_link\">",
"     \"Overview of pancreatic stenting and its complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR POST-ERCP PANCREATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatitis is the most common complication of diagnostic and therapeutic ERCP occurring in 1 to 15 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pancreas is subjected to many types of potential injury during ERCP and endoscopic sphincterotomy: mechanical, chemical, hydrostatic, enzymatic, microbiological, allergic, and thermal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/1\">",
"     1",
"    </a>",
"    ]. These mechanisms of injury may act independently or in concert to induce post-procedure pancreatitis. Several patient and procedure-related risk factors for post-ERCP pancreatitis have been found, which are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link\">",
"     \"Post-ERCP pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROPHYLACTIC STENTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of risk factors associated with post-ERCP pancreatitis provided the rationale for evaluating a number of measures for preventing post-ERCP pancreatitis. A possible approach is to use prophylactic pancreatic stents.",
"   </p>",
"   <p>",
"    Studies evaluating the use of prophylactic stents have included different indications for stenting, interventions, and outcome measures, and several have only been reported in preliminary form. As a result, the findings are not always directly comparable. Several randomized prospective trials evaluating stenting reached varying conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]. Some of the inconsistency may be due to variable rates of pancreatitis in the control groups, the degree of risk in the various patient populations, the power of the studies, and the endoscopic techniques used. Not surprisingly, the use of pancreatic stents is variable among expert biliary endoscopists [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/9\">",
"     9",
"    </a>",
"    ]; our approach is similar to that proposed by other authorities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Meta-analyses suggest that the use of stents decreases the rate of post-ERCP pancreatitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One meta-analysis included eight randomized trials with 656 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/11\">",
"       11",
"      </a>",
"      ]. The analysis of the randomized trials found that use of a prophylactic stent was associated with a decreased risk of post-ERCP pancreatitis (OR 0.22; 95% CI 0.12-0.38), with an absolute risk difference of 13 percent.",
"     </li>",
"     <li>",
"      A second meta-analysis of five prospective studies (not all randomized in design) found an overall benefit to stenting in patients at increased risk for post-ERCP pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients in the no stent group had threefold higher odds of developing pancreatitis compared with the stent group (15.5 versus 5.8 percent, OR 3.2). Perhaps most important was that no patient in the stented group developed severe pancreatitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individual trials that found stenting significantly decreased the risk of post-ERCP pancreatitis included the following types of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated with prophylactic pancreatic duct stents in the settings of pancreatic sphincter hypertension undergoing biliary sphincterotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients undergoing endoscopic ampullectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients with one or several risk factors for post-ERCP pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Consecutive patients with zero or more risk factors for post-ERCP pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A cost-effectiveness analysis indicated that pancreatic stent placement in high-risk patients yielded the highest number of life years gained compared with no placement or placement in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/12\">",
"     12",
"    </a>",
"    ]. These data need to be considered in the context of other experience (including results from uncontrolled studies), which will be reviewed below. Together, these form the basis for our recommendations. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     After excessive manipulations of the papilla",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data evaluating stenting in patients who underwent excessive manipulation of the papilla. In a randomized study, 76 high-risk patients (because of difficult cannulation, or because they were undergoing manometry or endoscopic sphincterotomy) were treated with a 5 Fr 2 cm pancreatic stent, a nasopancreatic drain, or no drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/2\">",
"     2",
"    </a>",
"    ]. The two stented groups had a significantly lower rate of post-ERCP pancreatitis (5 versus 28 percent).",
"   </p>",
"   <p>",
"    In a randomized trial of patients with difficult cannulation, placement of a 3 Fr pancreatic stent (4, 6, or 8 cm) was associated with a lower rate of post ERCP pancreatitis than no stent placement (12 versus 29 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/13\">",
"     13",
"    </a>",
"    ]. On multivariable analysis, pancreatic stent placement was the only factor associated with preventing post-ERCP pancreatitis (odds ratio 0.13; 95% confidence interval 0.03-0.63).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sphincter of Oddi dysfunction or a small bile duct",
"    </span>",
"    &nbsp;&mdash;&nbsp;A controlled trial included 98 patients with sphincter of Oddi dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a small diameter common bile duct who were randomly assigned to receive a main pancreatic duct stent (2 or 2.5 cm; 5 or 7 Fr) following the sphincterotomy or no stent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/3\">",
"     3",
"    </a>",
"    ]. The incidence of post-procedure pancreatitis (14 versus 18 percent) and the degree of amylase and lipase elevation (860 versus 1380",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    and 5978 versus 8121",
"    <span class=\"nowrap\">",
"     IU/L,",
"    </span>",
"    respectively) were reduced in the stented group, although the results were not statistically significant.",
"   </p>",
"   <p>",
"    Another study suggested that placing a pancreatic duct stent prior to combined pancreatic and biliary sphincterotomy (for therapy of sphincter of Oddi dysfunction) had a lower post-ERCP pancreatitis rate than biliary sphincterotomy alone (11 versus 28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that the risk of pancreatitis in patients with sphincter of Oddi dysfunction undergoing biliary sphincterotomy is related to underlying pancreatic sphincter hypertension. This hypothesis was supported in a prospective, randomized, controlled trial of 80 patients with manometrically proven pancreatic sphincter hypertension. Stenting of the pancreatic sphincter of Oddi segment (5 or 7 Fr) after biliary sphincterotomy significantly reduced the risk of pancreatitis (7 versus 26 percent with no stenting) (",
"    <a class=\"graphic graphic_table graphicRef81201 \" href=\"UTD.htm?14/13/14555\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results strongly suggest that this high-risk subset of patients (pancreatic sphincter hypertension undergoing biliary sphincterotomy alone) should be considered candidates for pancreatic stenting. However, the rate of pancreatitis in the control group was probably increased due to a number of patient and procedure-related risk factors.",
"   </p>",
"   <p>",
"    Another, retrospective study suggested that prophylactic stenting benefits those who were suspected of having SOD but had normal manometry [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/15\">",
"     15",
"    </a>",
"    ]. The study included 430 such patients, 115 of whom had a prophylactic stent placed at the discretion of the endoscopist. The rate of post-ERCP pancreatitis was only 0.9 percent in the stent group compared with 9.8 percent in the non-stent group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Precut sphincterotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the frequency of post-ERCP pancreatitis appears to be higher in patients undergoing precut sphincterotomy compared with those undergoing standard biliary sphincterotomy. One group evaluated the efficacy of placing a pancreatic duct stent prior to precut sphincterotomy and leaving it in place following the precut [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/16\">",
"     16",
"    </a>",
"    ]. During a 32-month interval, of 1122 patients undergoing sphincterotomy, 151 (13.5 percent) required precut sphincterotomy. In 93 patients, selective cannulation of the pancreatic duct was achieved and a 5 Fr or 7 Fr diameter, 2 or 2.5 cm length stent was placed in the pancreatic duct. Using the pancreatic duct stent as a guide, a needle-knife sphincterotomy was performed. Following completion of the sphincterotomy, these 93 patients were randomized to leaving the stent in place for 7 to 10 days (stent group) or immediate removal (stent removed group). The remaining 58 patients who did not undergo pancreatic duct stent placement (no stent group), had a needle-knife sphincterotomy performed in a similar fashion.",
"   </p>",
"   <p>",
"    Pancreatitis occurred significantly more often in the stent removed group compared with the stent group (21 versus 4 percent). Patients who did not have a pancreatic stent placed had a post-procedure pancreatitis rate of 14 percent. These data suggest that placing and maintaining a pancreatic duct stent following needle-knife precut sphincterotomy reduces the frequency of post-procedure pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pancreatic sphincterotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic pancreatic sphincterotomy has not been widely practiced because of lack of well-defined criteria for its use. In most studies in which it has been used, pancreatic sphincterotomy was performed as an adjunctive therapy to allow access to the pancreatic duct for other maneuvers (eg, stone removal, stent placement, and tissue sampling). There are limited data regarding the use of pancreatic sphincterotomy alone to treat disorders of the pancreas or sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of stenting when a pancreatic sphincterotomy is required can be understood in the context of the two standard methods to cut the pancreatic sphincter (minor or major) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/18\">",
"     18",
"    </a>",
"    ]. One method involves placement of a standard pull-type sphincterotome in the pancreatic duct oriented along the axis of the pancreatic duct. An incision of 5 to 10 mm is usually made. A second method uses a needle-knife to perform the sphincterotomy over a previously placed pancreatic stent. In the former technique, a pancreatic stent is usually placed after the sphincterotomy, particularly when the pancreatic duct is normal (eg, in the setting of sphincter of Oddi dysfunction or pancreas divisum).",
"   </p>",
"   <p>",
"    Accumulating data suggest that placement of a pancreatic stent in this setting can reduce the incidence of post-pancreatic sphincterotomy pancreatitis. This approach was supported in a retrospective study in which the frequency of post-pancreatic sphincterotomy pancreatitis was determined in 164 patients treated with overnight nasopancreatic catheter drainage (60 percent), pancreatic stenting (30 percent), or no drainage (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/17\">",
"     17",
"    </a>",
"    ]. The type of pancreatic drainage used varied according to the indication for the sphincterotomy. Patients undergoing pancreatic sphincterotomy as the primary therapy (without other treatments) more commonly had a nasopancreatic catheter placed (94 versus 6 percent for stent). In contrast, when the sphincterotomy was done as an adjunct for further interventions, the method of drainage was more commonly a pancreatic stent (71 versus 29 percent for a nasopancreatic catheter).",
"   </p>",
"   <p>",
"    Post-ERCP pancreatitis occurred in three patients (2 percent) and was graded mild in two and moderate in one. Pancreatitis occurred significantly less often in patients treated by a nasopancreatic catheter or a pancreatic stent compared to those not undergoing a drainage procedure (2 and 0 versus 13 percent, respectively) (",
"    <a class=\"graphic graphic_table graphicRef78326 \" href=\"UTD.htm?3/36/3659\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The authors concluded that a drainage catheter or stent is required after pancreatic sphincterotomy to reduce the incidence of pancreatitis. They suggested that nasopancreatic drainage is the method of choice, since it has a similar complication rate as stenting, avoids the need for a repeat procedure to remove the stent, and presumably avoids the other complications associated with stenting because of the extremely short period (usually less than 24 hours) of drainage (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Complications of pancreatic stents'",
"    </a>",
"    below). However, pancreatic stents without an internal flange have a high spontaneous migration rate out of the duct and are much more commonly used in clinical practice than nasopancreatic drains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Balloon sphincter dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible benefit to prophylactic pancreatic stent placement was suggested in a study of 40 patients with bile duct stones [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/19\">",
"     19",
"    </a>",
"    ]. The study compared patients who had a stent placed prior to balloon dilation of the sphincter of Oddi to historic controls who did not have stent placed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/19\">",
"     19",
"    </a>",
"    ]. The postprocedure serum amylase level was significantly less in the group who received a stent. A nonstatistically significant trend toward a lower rate of pancreatitis was also observed. The nonrandomized study design, small sample size, and unclear clinical benefit limit the conclusions that can be derived from this report. Furthermore, the modest treatment benefit (if any) and the need for a follow-up procedure to remove the stent raises questions about the cost-effectiveness of stenting in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37175?source=see_link\">",
"     \"Endoscopic balloon dilatation for removal of bile duct stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Snare excision of the duodenal ampulla",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduced risk of pancreatitis with pancreatic stent insertion was found in a controlled trial of patients undergoing snare excisions of the duodenal ampulla [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13897?source=see_link\">",
"     \"Treatment of ampullary adenomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Routine prophylactic pancreatic duct stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized controlled multicenter study from Japan evaluated the efficacy of a pancreatic stent without an internal flange in 201 consecutive patients undergoing ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/6\">",
"     6",
"    </a>",
"    ]. Many of the patients in this study would not have been considered high-risk.",
"   </p>",
"   <p>",
"    Ninety-eight patients received a 5F straight polyethylene stent, 3 cm in length, unflanged on the pancreatic ductal side and with two flanges on the duodenal side (S group) and 103 patients did not receive a stent. Stent dislodgement was confirmed by daily abdominal X-rays with stent removal if dislodgement did not occur by day 4. All patients in the study were given antibiotics and gabexate mesylate after the ERCP.",
"   </p>",
"   <p>",
"    The diagnosis and grading of the severity of pancreatitis were based on standardized criteria. Patient demographics, procedure indication, difficulty of cannulation, grade of ERCP skill of the endoscopist, procedure time, and procedures performed were similar for the two groups. Pancreatic stents were successfully placed in 96 percent and the rate of stent dislodgement by day 3 was 95.7 percent.",
"   </p>",
"   <p>",
"    The overall frequency of pancreatitis was 8.5 percent (17 of 201). It occurred significantly less often in the stent group compared to the nonstent group (3.2 versus 13.6 percent). The mean increase in serum amylase level in pancreatitis patients, the overall serum amylase levels, and the frequency of abdominal pain were significantly higher in the nonstent group. There were no episodes of severe post-ERCP pancreatitis in either group. There were no major complications related to stenting and pancreatitis did not occur in the four patients who failed stent placement. This study shows that placement of unflanged stents leads to a high stent migration rate, thus avoiding a second procedure to remove the stents, and provides protection against post-ERCP pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Facilitating bile duct cannulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of a pancreatic stent may have a role in facilitating difficult bile duct cannulation. A 99 percent success rate using this approach was described in a series of 39 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/20\">",
"     20",
"    </a>",
"    ]. Two patients (5 percent) developed post-ERCP pancreatitis, both mild.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF PANCREATIC STENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the results of the above studies strongly suggest that pancreatic stenting reduces the incidence of post-ERCP pancreatitis in certain subgroups of patients, the endoscopist should be aware that pancreatic stenting has a clear downside. A variety of complications directly related to the pancreatic stent can occur, including stent occlusion (occasionally associated with pancreatitis or pain), migration into or out of the duct (the former may require surgery for stent removal), duodenal erosions, infection, ductal perforation, and morphologic changes of the pancreatic duct and parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The morphologic changes are concerning particularly when they occur in a previously normal pancreas. In seven published series, new morphologic pancreatic ductal changes were seen in 54 percent of 297 patients stented [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/21,23-28\">",
"     21,23-28",
"    </a>",
"    ]. The risk may be reduced by using small (3 to 4 Fr), unflanged stents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be appreciated that the risk of pancreatitis after failing to place a pancreatic stent may be greater than no attempt at all [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=see_link\">",
"     \"Overview of pancreatic stenting and its complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another downside of placing a prophylactic pancreatic stent is the need in may cases for a second endoscopy to remove the stent. As a result, some authorities advocate placement of a nasopancreatic tube since it can easily be removed at the bedside within 24 hours of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Prophylactic stenting'",
"    </a>",
"    above.) However, it is possible that small caliber stents may be effective while (because of their tendency to spontaneously dislodge) avoiding the need for a second endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. This issue was addressed in a study that compared the spontaneous dislodgement rates of small diameter (3 Fr and 4 Fr), long length (8 to 12 cm), and no intraductal flange pancreatic stents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/31\">",
"     31",
"    </a>",
"    ]. Eighty-six percent of 3 Fr stents spontaneously passed within 30 days (compared with 73, 67, and 65 percent of 4 Fr, 5 Fr, and 6 Fr stents, respectively).",
"   </p>",
"   <p>",
"    In the Japanese study described above, stent passage was recognized in 96 percent of patients after an average of two days when using a \"spontaneous dislodgement stent\" [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22983/abstract/6\">",
"     6",
"    </a>",
"    ]. The stent was 5F, straight, polyethylene, 3 cm in length, unflanged on the pancreatic side and with two flanges on the duodenal side (GPDS-5-2; Cook Endoscopy Inc, Winston-Salem, NC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considering the above discussion, available evidence, and clinical experience, we suggest the approaches outlined below with regard to prophylactic pancreatic stent placement to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. These recommendations are based upon the assumption that a highly skilled endoscopist with experience in pancreatic stenting is available. In other settings, the benefit of stenting may be outweighed by the risk of excessive and potentially unsuccessful pancreatic duct manipulation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest pancreatic stents be placed in patients undergoing ERCP in the following settings (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Those undergoing pancreatic endotherapy",
"     </li>",
"     <li>",
"      Suspected or documented sphincter of Oddi dysfunction (SOD)",
"     </li>",
"     <li>",
"      Prior post-ERCP pancreatitis",
"     </li>",
"     <li>",
"      Difficult cannulation",
"     </li>",
"     <li>",
"      Precut sphincterotomy starting at the papillary orifice",
"     </li>",
"     <li>",
"      Pancreatic sphincterotomy (major or minor)",
"     </li>",
"     <li>",
"      Aggressive instrumentation of the pancreatic duct (such as brush cytology)",
"     </li>",
"     <li>",
"      Balloon dilation of an intact sphincter",
"     </li>",
"     <li>",
"      Endoscopic ampullectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients considered high-risk for post-ERCP pancreatitis, it is reasonable to attempt filling of the pancreatic duct in patients in whom it was not filled during attempts at biliary cannulation. If the pancreatic duct fills easily, and the anatomy is favorable, placement of a stent is reasonable. In other patients, the benefit of aggressive attempts at pancreatic duct filling or stenting may be outweighed by associated trauma.",
"     </li>",
"     <li>",
"      Prophylactic pancreatic duct stenting is generally not recommended in low-risk patients, in patients undergoing needle-knife precut or fistulotomy starting above the papillary orifice in the absence of other risk factors, or if the pancreatic duct is not injected with contrast and there is limited guidewire manipulation in an otherwise low-risk patient.",
"     </li>",
"     <li>",
"      In patients with suspected SOD, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      performing empiric pancreatic duct stenting as a primary therapy or as a trial to predict response from pancreatic sphincterotomy, primarily because of stent-related complications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such patients should undergo sphincter of Oddi manometry and definitive therapy (sphincter ablation) when indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29126?source=see_link\">",
"       \"Treatment of sphincter of Oddi dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients undergoing prophylactic pancreatic duct stenting, we suggest a stent be left in place for at least 24 hours and preferably less than 14 days (particularly if the pancreatic duct has normal morphology) depending upon stent size.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/1\">",
"      Sherman S. ERCP and endoscopic sphincterotomy-induced pancreatitis. Am J Gastroenterol 1994; 89:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/2\">",
"      Fazel A, Quadri A, Catalano MF, et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc 2003; 57:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/3\">",
"      Smithline A, Silverman W, Rogers D, et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 1993; 39:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/4\">",
"      Tarnasky PR, Palesch YY, Cunningham JT, et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998; 115:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/5\">",
"      Harewood GC, Pochron NL, Gostout CJ. Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla. Gastrointest Endosc 2005; 62:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/6\">",
"      Sofuni A, Maguchi H, Itoi T, et al. Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol 2007; 5:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/7\">",
"      Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 2004; 60:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/8\">",
"      Sofuni A, Maguchi H, Mukai T, et al. Endoscopic pancreatic duct stents reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients. Clin Gastroenterol Hepatol 2011; 9:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/9\">",
"      Brackbill S, Young S, Schoenfeld P, Elta G. A survey of physician practices on prophylactic pancreatic stents. Gastrointest Endosc 2006; 64:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/10\">",
"      Freeman ML. Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007; 5:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/11\">",
"      Choudhary A, Bechtold ML, Arif M, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc 2011; 73:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/12\">",
"      Das A, Singh P, Sivak MV Jr, Chak A. Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis. Gastrointest Endosc 2007; 65:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/13\">",
"      Lee TH, Moon JH, Choi HJ, et al. Prophylactic temporary 3F pancreatic duct stent to prevent post-ERCP pancreatitis in patients with a difficult biliary cannulation: a multicenter, prospective, randomized study. Gastrointest Endosc 2012; 76:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/14\">",
"      Fogel EL, Eversman D, Jamidar P, et al. Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy 2002; 34:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/15\">",
"      Saad AM, Fogel EL, McHenry L, et al. Pancreatic duct stent placement prevents post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction but normal manometry results. Gastrointest Endosc 2008; 67:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/16\">",
"      Cha SW, Leung WD, Lehman GA, et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-associated pancreatitis? A randomized, prospective study. Gastrointest Endosc 2013; 77:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/17\">",
"      Elton E, Howell DA, Parsons WG, et al. Endoscopic pancreatic sphincterotomy: indications, outcome, and a safe stentless technique. Gastrointest Endosc 1998; 47:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/18\">",
"      Sherman S, Lehman GA. Endoscopic pancreatic sphincterotomy: techniques and complications. Gastrointest Endosc Clin N Am 1998; 8:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/19\">",
"      Aizawa T, Ueno N. Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones. Gastrointest Endosc 2001; 54:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/20\">",
"      Goldberg E, Titus M, Haluszka O, Darwin P. Pancreatic-duct stent placement facilitates difficult common bile duct cannulation. Gastrointest Endosc 2005; 62:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/21\">",
"      Smith MT, Sherman S, Ikenberry SO, et al. Alterations in pancreatic ductal morphology following polyethylene pancreatic stent therapy. Gastrointest Endosc 1996; 44:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/22\">",
"      Sherman S, Hawes RH, Savides TJ, et al. Stent-induced pancreatic ductal and parenchymal changes: correlation of endoscopic ultrasound with ERCP. Gastrointest Endosc 1996; 44:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/23\">",
"      Derfus GA, Geenen JE, Hogan WJ. Effect of endoscopic pancreatic duct stent placement on pancreatic ductal morphology (abstract). Gastrointest Endosc 1990; 36:206A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/24\">",
"      Kozarek RA. Pancreatic stents can induce ductal changes consistent with chronic pancreatitis. Gastrointest Endosc 1990; 36:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/25\">",
"      Rossos PG, Kortan P, Haber GB. Complications associated with pancreatic duct stenting (abstract). Gastrointest Endosc 1992; 38:252A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/26\">",
"      Burdick JS, Geenen JE, Venue RP, et al. Ductal morphological changes due to pancreatic stent therapy: A randomized controlled study (abstract). Am J Gastroenterol 1992; 87:155A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/27\">",
"      Lehman GA, Sherman S, Nisi R, Hawes RH. Pancreas divisum: results of minor papilla sphincterotomy. Gastrointest Endosc 1993; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/28\">",
"      Eisen G, Coleman S, Troughton A, Cotton PB. Morphological changes in the pancreatic duct after stent placement for benign pancreatic disease (abstract). Gastrointest Endosc 1994; 40:107A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/29\">",
"      Lawrence C, Cotton PB, Romagnuolo J, et al. Small prophylactic pancreatic duct stents: an assessment of spontaneous passage and stent-induced ductal abnormalities. Endoscopy 2007; 39:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/30\">",
"      Freeman ML, Overby C, Qi D. Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success. Gastrointest Endosc 2004; 59:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22983/abstract/31\">",
"      Rashdan A, Fogel EL, McHenry L Jr, et al. Improved stent characteristics for prophylaxis of post-ERCP pancreatitis. Clin Gastroenterol Hepatol 2004; 2:322.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2661 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22983=[""].join("\n");
var outline_f22_28_22983=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS FOR POST-ERCP PANCREATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROPHYLACTIC STENTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      After excessive manipulations of the papilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sphincter of Oddi dysfunction or a small bile duct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Precut sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pancreatic sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Balloon sphincter dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Snare excision of the duodenal ampulla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Routine prophylactic pancreatic duct stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Facilitating bile duct cannulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS OF PANCREATIC STENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2661\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2661|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/17/19739\" title=\"table 1\">",
"      Uses of pancreatic stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/13/14555\" title=\"table 2\">",
"      Pancreatic sphnctr HTN stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/36/3659\" title=\"table 3\">",
"      Efficacy pancreatic drainage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=related_link\">",
"      Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37175?source=related_link\">",
"      Endoscopic balloon dilatation for removal of bile duct stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=related_link\">",
"      Overview of pancreatic stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=related_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13897?source=related_link\">",
"      Treatment of ampullary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29126?source=related_link\">",
"      Treatment of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_28_22984="Prochlorperazine: Drug information";
var content_f22_28_22984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prochlorperazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/50/33573?source=see_link\">",
"    see \"Prochlorperazine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/14/5351?source=see_link\">",
"    see \"Prochlorperazine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7290570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Compro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Prochlorperazine&reg;;",
"     </li>",
"     <li>",
"      Nu-Prochlor;",
"     </li>",
"     <li>",
"      PMS-Prochlorperazine;",
"     </li>",
"     <li>",
"      Sandoz-Prochlorperazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F213858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic;",
"     </li>",
"     <li>",
"      Antipsychotic Agent, Typical, Phenothiazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F213833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Injection solution mesylate formulation has Canadian availability (not available in U.S.).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Antiemetic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral",
"     </i>",
"     (tablet): 5-10 mg 3-4 times/day; usual maximum: 40 mg/day; larger doses may rarely be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (as edisylate):",
"     </i>",
"     5-10 mg every 3-4 hours; usual maximum: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (as mesylate):",
"     </i>",
"     5-10 mg 2-3 times/day; usual maximum: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. (as edisylate):",
"     </i>",
"     2.5-10 mg; maximum: 10 mg/dose or 40 mg/day; may repeat dose every 3-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Rectal:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     U.S. labeling: 25 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Canadian labeling: 5-10 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Surgical nausea/vomiting:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Should not exceed 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (as edisylate):",
"     </i>",
"     5-10 mg 1-2 hours before anesthesia induction or to control symptoms during or after surgery; may repeat once if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (as mesylate):",
"     </i>",
"     5-10 mg 1-2 hours before anesthesia induction; may repeat once if needed during surgery; postoperatively: 5-10 mg every 3-4 hours as needed up to maximum of 40 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. (as edisylate):",
"     </i>",
"     5-10 mg 15-30 minutes before anesthesia induction or to control symptoms during or after surgery; may repeat once if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. (as mesylate):",
"     </i>",
"     20 mg/L of I.V. solution during surgery or postoperatively; usual maximum: 30 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Rectal (unlabeled use; Golembiewski, 2005):",
"     </i>",
"     25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Antipsychotic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     5-10 mg 3-4 times/day; titrate dose slowly every 2-3 days; doses up to 150 mg/day may be required in some patients for treatment of severe disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (as edisylate):",
"     </i>",
"     Initial: 10-20 mg; if necessary repeat initial dose every 2-4 hours to gain control; more than 3-4 doses are rarely needed. If parenteral administration is still required; give 10-20 mg every 4-6 hours; convert to oral therapy as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (as mesylate):",
"     </i>",
"     Initial: 10-20 mg; if necessary repeat initial dose every 2-4 hours to gain control; more than 3-4 doses are rarely needed; convert to oral therapy as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonpsychotic anxiety:",
"     </b>",
"     <i>",
"      Oral (tablet):",
"     </i>",
"     Usual dose: 5 mg 3-4 times/day; do not exceed 20 mg/day or administer &gt;12 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F213848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/14/5351?source=see_link\">",
"      see \"Prochlorperazine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Injection solution mesylate formulation has Canadian availability (not available in U.S.).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Use is contraindicated in children &lt;9 kg or &lt;2 years.",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiemetic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral, rectal",
"     </i>",
"     (therapy &gt;1 day usually not required):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      9-13 kg:",
"     </i>",
"     2.5 mg 1-2 times/day as needed (maximum: 7.5 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      &gt;13-18 kg:",
"     </i>",
"     2.5 mg 2-3 times/day as needed (maximum: 10 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      &gt;18-39 kg:",
"     </i>",
"     2.5 mg 3 times/day or 5 mg 2 times/day as needed (maximum: 15 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (as edisylate):",
"     </i>",
"     0.13 mg/kg/dose; convert to oral therapy as soon as possible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (as mesylate):",
"     </i>",
"     0.14 mg/kg/dose; convert to oral therapy at equivalent or greater dose (if necessary) as soon as possible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antipsychotic:",
"     </b>",
"     Children 2-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Oral, rectal:",
"     </i>",
"     2.5 mg 2-3 times/day; do not give more than 10 mg the first day; increase dosage as needed to maximum daily dose of 20 mg for 2-5 years and 25 mg for 6-12 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      I.M. (as edisylate):",
"     </i>",
"     0.13 mg/kg/dose; convert to oral therapy as soon as possible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      I.M. (as mesylate):",
"     </i>",
"     0.14 mg/kg/dose; convert to oral therapy at equivalent or greater dose (if necessary) as soon as possible",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F213834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initiate at lower end of dosage range; titrate slowly and cautiously. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14632658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14632659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; systemic exposure may be increased as drug undergoes hepatic metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as edisylate [strength expressed as base]: 5 mg/mL (2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal: 25 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compro&reg;: 25 mg (12s) [contains coconut oil, palm oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate [strength expressed as base]: 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F14632698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as mesylate [strength expressed as base]: 5 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal: 10 mg (10s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F213806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Inject by deep I.M. into outer quadrant of buttocks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: May be administered by slow I.V. push at a rate not exceeding 5 mg/minute or by I.V. infusion. Do not administer as a bolus injection. To reduce the risk of hypotension, patients receiving I.V. prochlorperazine must remain lying down and be observed for at least 30 minutes following administration. Avoid skin contact with injection solution, contact dermatitis has occurred. Do not dilute with any diluent containing parabens as a preservative.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer tablet without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F213865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amsacrine, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doxorubicin, doxorubicin liposome, fluconazole, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, linezolid, melphalan, methotrexate, methylprednisolone sodium succinate, ondansetron, oxaliplatin, paclitaxel, potassium chloride, propofol, remifentanil, sargramostim, sufentanil, teniposide, thiotepa, topotecan, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aldesleukin, allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, aztreonam, bivalirudin, cefepime, etoposide phosphate, fenoldopam, filgrastim, fludarabine, foscarnet, gemcitabine, pantoprazole, pemetrexed, piperacillin/tazobactam, vitamin B complex with C.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Calcium gluconate, gallium nitrate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, butorphanol, chlorpromazine, cimetidine, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydroxyzine, meperidine, metoclopramide, nalbuphine, pentazocine, promethazine, ranitidine, scopolamine, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dimenhydrinate, ketorolac, midazolam, pantoprazole, pentobarbital, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Hydromorphone, morphine sulfate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F213805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of nausea and vomiting; psychotic disorders, including schizophrenia and anxiety; nonpsychotic anxiety",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F213855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Behavioral syndromes in dementia; psychosis/agitation related to Alzheimer's dementia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F213867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Prochlorperazine may be confused with chlorproMAZINE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Compazine may be confused with Copaxone&reg;, Coumadin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       CPZ (occasional abbreviation for Compazine) is an error-prone abbreviation (mistaken as chlorpromazine)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F213856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reported with prochlorperazine or other phenothiazines. Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, cerebral edema, hypotension, peripheral edema, Q-wave distortions, sudden death, T-wave distortions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, altered cerebrospinal fluid proteins, catatonia, coma, cough reflex suppressed, dizziness, drowsiness, fever (mild [I.M.]), headache, hyperpyrexia, impairment of temperature regulation, insomnia, neuroleptic malignant syndrome (NMS), oculogyric crisis, opisthotonos, restlessness, seizure, somnolence, tremulousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, contact dermatitis, epithelial keratopathy, erythema, eczema, exfoliative dermatitis, itching, photosensitivity, skin pigmentation, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, galactorrhea, gynecomastia, glucosuria, hyper-/hypoglycemia, lactation, libido (changes in), menstrual irregularity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased, atonic colon, constipation, ileus, nausea, obstipation, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ejaculating dysfunction, ejaculatory disturbances, impotence, priapism, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Biliary stasis, cholestatic jaundice, hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dystonias (torticollis, carpopedal spasm, trismus, protrusion of tongue); extrapyramidal symptoms (pseudoparkinsonism, akathisia, dystonias, tardive dyskinesia, hyperreflexia); SLE-like syndrome, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, lenticular/corneal deposits, miosis, mydriasis, pigmentary retinopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, laryngeal edema, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, asphyxia, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F213809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to prochlorperazine or any component of the formulation (cross-reactivity between phenothiazines may occur); coma or presence of large amounts of CNS depressants (eg, alcohol, narcotics, barbiturates); pediatric surgery; children &lt;2 years of age or &lt;9 kg",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Presence of circulatory collapse; severe cardiovascular disorders; altered state of consciousness; concomitant use of high dose hypnotics; severe depression; presence of blood dyscrasias, hepatic or renal impairment, or pheochromocytoma; suspected or established subcortical brain damage with or without hypothalamic damage",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F213791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction (life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of dystonia (and possibly other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Risk of tardive dyskinesia and potential for irreversibility often associated with total cumulative dose and therapy duration and may also be increased in elderly patients (particularly elderly women); antipsychotics may also mask signs/symptoms of tardive dyskinesia. Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: Use associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May occur following administration, particularly when parenteral form is used or in high dosages. May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): May be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: May cause pigmentary retinopathy, and lenticular and corneal deposits, particularly with prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Prochlorperazine is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Canadian labeling contraindicates use in hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; they may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Canadian labeling contraindicates use in renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reye&rsquo;s syndrome: Avoid use in patients with signs/symptoms suggestive of Reye&rsquo;s syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: May be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) due to its potent anticholinergic effects (Beers Criteria). Use with caution in the elderly; increased risk for developing tardive dyskinesia, particularly elderly women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children with acute illness or dehydration are more susceptible to neuromuscular reactions (eg, dystonias); use cautiously.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some dosage forms may contain benzyl alcohol which has been associated  with &ldquo;gasping syndrome&rdquo; in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium sulfite: Some dosage forms may contain sodium sulfite.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferoxamine: May enhance the adverse/toxic effect of Prochlorperazine. Specifically, prolonged loss of consciousness has been reported.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Prochlorperazine may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F213825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai, St John's wort (may also cause photosensitization). Avoid kava kava, gotu kola, valerian, St John's wort (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F213813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice or hyper-/hyporeflexia have been reported in newborn infants following maternal use of phenothiazines. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F213841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F1181961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Other phenothiazines are excreted in human milk; excretion of prochlorperazine is not known.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F213814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase dietary intake of riboflavin; should be administered with food or water. Rectal suppositories may contain coconut and palm oil.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F213812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Prochlorperazine Edisylate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (2 mL): $5.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Compro Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (12): $50.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Prochlorperazine Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (12): $160.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Prochlorperazine Maleate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $59.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $89.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F213801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; CBC (baseline, frequently during first few months of therapy, periodically thereafter); lipid profile; fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI; mental status; abnormal involuntary movement scale (AIMS); periodic ophthalmic exams (if chronically used); extrapyramidal symptoms (EPS)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antinaus (NZ);",
"     </li>",
"     <li>",
"      Buccastem (NZ);",
"     </li>",
"     <li>",
"      Buccastem 3 (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Chloropernazinum (PL);",
"     </li>",
"     <li>",
"      Dhaperazine (HK, MY);",
"     </li>",
"     <li>",
"      Nautisol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Novamin (TW);",
"     </li>",
"     <li>",
"      Prochlor (MY);",
"     </li>",
"     <li>",
"      Proclozine (TH);",
"     </li>",
"     <li>",
"      Protazine (MY);",
"     </li>",
"     <li>",
"      Stemetil (AE, AU, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, DK, EG, ET, FI, GB, GH, GM, GN, GY, ID, IE, IL, IN, IQ, IT, JM, KE, KW, LR, MA, ML, MR, MU, MW, NE, NG, NL, NO, NZ, OM, PK, QA, SC, SD, SE, SG, SL, SN, SR, TH, TN, TT, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Stemzine (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F213790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prochlorperazine is a piperazine phenothiazine antipsychotic which blocks postsynaptic mesolimbic dopaminergic D",
"     <sub>",
"      1",
"     </sub>",
"     and D",
"     <sub>",
"      2",
"     </sub>",
"     receptors in the brain, including the chemoreceptor trigger zone; exhibits a strong alpha-adrenergic and anticholinergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones; believed to depress the reticular activating system, thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone and emesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F213808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 30-40 minutes; I.M.: 10-20 minutes; Rectal: ~60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak antiemetic effect: I.V.: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Rectal: 3-12 hours; I.M., Oral: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1400-1548 L (Taylor, 1987); crosses placenta; enters breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic; N-desmethyl prochlorperazine (major active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 12.5% (Isah, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: 6-10 hours (single dose), 14-22 hours (repeated dosing) (Isah, 1991); I.V.: 6-10 hours (Isah, 1991; Taylor, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Mainly in feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ernst AA, Weiss SJ, Park S, et al, &ldquo;Prochlorperazine Versus Promethazine for Uncomplicated Nausea and Vomiting in the Emergency Department: A Randomized, Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2000, 36(2):89-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/10918098/pubmed\" id=\"10918098\" target=\"_blank\">",
"        10918098",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Meyer TA, Apfel CC, et al, &ldquo;Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 105(6):1615-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/18042859/pubmed\" id=\"18042859\" target=\"_blank\">",
"        18042859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldstein D, Levi JA, Woods RL, et al, &ldquo;Double-Blind Randomized Cross-Over Trial of Dexamethasone and Prochlorperazine as Antiemetics for Cancer Chemotherapy,&rdquo;",
"      <i>",
"       Oncology",
"      </i>",
"      , 1989, 46(2):105-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/2652018/pubmed\" id=\"2652018\" target=\"_blank\">",
"        2652018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Golembiewski J, Chernin E, and Chopra T, &ldquo;Prevention and Treatment of Postoperative Nausea and Vomiting,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2005, 62(12):1247-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/15947124/pubmed\" id=\"15947124\" target=\"_blank\">",
"        15947124",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hesketh PJ, Gandara DR, Hesketh AM, et al, &ldquo;Improved Control of High-Dose-Cisplatin-Induced Acute Emesis With the Addition of Prochlorperazine to Granisetron/Dexamethasone,&rdquo;",
"      <i>",
"       Cancer J Sci Am",
"      </i>",
"      , 1997, 3(3):180-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/9161784/pubmed\" id=\"9161784\" target=\"_blank\">",
"        9161784",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Isah AO, Rawlins MD, and Bateman DN, &ldquo;Clinical Pharmacology of Prochlorperazine in Healthy Young Males,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1991, 32(6):677-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/1768559/pubmed\" id=\"1768559\" target=\"_blank\">",
"        1768559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health, &ldquo;Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated),&rdquo; National Clinical Practice Guideline Number 82, 2009:1-399. Available at  www.nice.org.uk/cg082",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olver IN, Webster LK, Bishop JF, et al, &ldquo;A Dose Finding Study of Prochlorperazine as an Antiemetic for Cancer Chemotherapy,&rdquo;",
"      <i>",
"       Eur J Cancer Clin Oncol",
"      </i>",
"      , 1989, 25(10):1457-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/2591437/pubmed\" id=\"2591437\" target=\"_blank\">",
"        2591437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Owens NH, Schauer AR, Nightingale CH, et al, &ldquo;Antiemetic Efficacy of Prochlorperazine, Haloperidol, Droperidol in Cisplatin-Induced Emesis,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1984, 3(2):167-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/6373102/pubmed\" id=\"6373102\" target=\"_blank\">",
"        6373102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor WB and Bateman DN, &ldquo;Preliminary Studies of the Pharmacokinetics and Pharmacodynamics of Prochlorperazine in Healthy Volunteers,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1987, 23(2): 137-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/28/22984/abstract-text/3828192/pubmed\" id=\"3828192\" target=\"_blank\">",
"        3828192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9816 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22984=[""].join("\n");
var outline_f22_28_22984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290570\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213829\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213830\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213858\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213833\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213848\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213834\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14632658\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14632659\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213803\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14632698\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213787\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213806\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213865\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213805\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213855\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213867\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213856\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213809\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213791\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299946\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213796\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213825\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213813\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213841\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181961\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213814\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213812\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213801\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038782\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213790\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213808\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9816\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9816|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/50/33573?source=related_link\">",
"      Prochlorperazine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/14/5351?source=related_link\">",
"      Prochlorperazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_28_22985="Vertebral osteomyelitis and discitis";
var content_f22_28_22985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vertebral osteomyelitis and discitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/28/22985/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/28/22985/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/28/22985/contributors\">",
"     Malcolm McDonald, PhD, FRACP, FRCPA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/28/22985/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/28/22985/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/28/22985/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/28/22985/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/28/22985/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertebral osteomyelitis was recognized as a distinct clinical entity by Hippocrates and Galen. Prior to the discovery of antibiotics, vertebral osteomyelitis was fatal in approximately 25 percent of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/1\">",
"     1",
"    </a>",
"    ]. Mortality is now rare, but morbidity is common; in addition, delays in diagnosis can lead to disabling complications.",
"   </p>",
"   <p>",
"    The terms vertebral osteomyelitis and discitis are often used interchangeably by clinicians. As the disc space has no direct blood supply in adults, this space is secondarily involved when a hematogenous infection spreads to bone and subsequently spreads to the adjacent intervertebral disc space. However, infection can also spread from the disc space to adjacent bone when infection arises after surgery or following disc space injections. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For the purposes of this discussion, the terms vertebral osteomyelitis and discitis will be used interchangeably as the diagnosis and management of the two entities is similar in most patients.",
"   </p>",
"   <p>",
"    Pyogenic vertebral osteomyelitis will be reviewed here. The closely related topics of spinal epidural abscess and tuberculous spinal infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=see_link\">",
"     \"Epidural abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"     \"Skeletal tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertebral osteomyelitis is primarily a disease of adults, with the majority of patients being more than 50 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/2\">",
"     2",
"    </a>",
"    ]. As a general rule, the age-adjusted incidence increases progressively with each successive decade of life. Men are affected approximately twice as often as women in most case series; the reason for this male predominance is not clearly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is difficult to obtain reliable information on the overall incidence of vertebral osteomyelitis. In two studies published in 1979 and 2001, the incidence of spinal osteomyelitis was estimated to be 1:250,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/3\">",
"     3",
"    </a>",
"    ] and 1:450,000, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/4\">",
"     4",
"    </a>",
"    ]. However, most authorities believe that the overall incidence of vertebral osteomyelitis has steadily increased in recent years for three primary reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increasing rates of nosocomial bacteremia due to intravascular devices and other forms of instrumentation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"       \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increasing age of the population",
"     </li>",
"     <li>",
"      Injection drug use",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathogens can reach the bones of the spine by three basic routes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39269?source=see_link\">",
"     \"Pathogenesis of osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematogenous spread from a distant site or focus of infection",
"     </li>",
"     <li>",
"      Direct inoculation from trauma or spinal surgery",
"     </li>",
"     <li>",
"      Contiguous spread from adjacent soft tissue infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it was previously thought that spread of infection might occur via vertebral veins known as Batson's plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], this theory has been discounted.",
"   </p>",
"   <p>",
"    Potential sources of hematogenous or contiguous spread of infection include the genitourinary tract, skin and soft tissue (eg, injection drug use), respiratory tract, infected intravenous catheter sites, postoperative wound infection, endocarditis, and dental infection. In many patients, however, the primary site of infection cannot be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/7\">",
"     7",
"    </a>",
"    ]. Less common causes include infected native or prosthetic valvular infections, direct spread from a ruptured esophagus, diverticular or renal abscesses, and infected aortic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/8\">",
"     8",
"    </a>",
"    ]. Vertebral osteomyelitis rarely occurs as a complication of lumbar puncture, myelography, translumbar aortography, chemonucleolysis, discography, facet joint corticosteroid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/9\">",
"     9",
"    </a>",
"    ], epidural catheter placement, or epidural corticosteroid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hematogenous spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematogenous spread is by far the most common cause of vertebral osteomyelitis. The mechanism by which bacteria in the bloodstream cause vertebral osteomyelitis is complex. Unlike long bones whose metaphyseal marrow cavity is composed of relatively avascular adipose tissue, vertebral bone in adults has abundant, highly vascular marrow with a sluggish but high-volume blood flow via nutrient vessels of the posterior spinal artery. In addition, these vessels progressively develop a characteristic \"corkscrew\" anatomy with aging that may predispose to bacterial hematogenous seeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood-borne organisms that randomly percolate through the marrow cavity of the vertebrae can spontaneously produce a local suppurative infection. Initiation of infection may be facilitated by recent or prior bone trauma with disruption of normal architecture.",
"   </p>",
"   <p>",
"    The segmental arteries supplying the vertebrae usually bifurcate to supply two adjacent end plates of contiguous vertebrae. Thus, hematogenous vertebral osteomyelitis usually causes bone destruction in two adjacent vertebral bodies and their intervertebral disc. The lumbar vertebral bodies are most often involved, followed in frequency by the thoracic, and rarely cervical vertebrae.",
"   </p>",
"   <p>",
"    Contiguous spread of infection may occur from tissues such as the aorta, esophagus, or bowel that are adjacent to the spine. Extension of infection, in such cases, is facilitated by the absence of a circumferential cartilage plate or a layer of subchondral compact bone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/1\">",
"     1",
"    </a>",
"    ]. Posterior extension can lead to epidural and subdural abscesses or even meningitis, while anterior or lateral extension can lead to paravertebral, retropharyngeal, mediastinal, subphrenic, retroperitoneal, or psoas abscesses. Thoracic vertebral infections can also extend into the pleural space to produce an empyema [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection occasionally arises in spinal elements other than the vertebral bodies. These include the posterior processes, the facet joints and rarely the odontoid process [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important infecting organism in pyogenic spinal osteomyelitis is Staphylococcus aureus, accounting for more than 50 percent of cases in most series from developed countries. As the proportion of S. aureus strains that are methicillin-resistant (MRSA) has increased during the past decade, the relative importance of MRSA as a cause of vertebral osteomyelitis has simultaneously increased. However, the range of reported pathogens is large; less common but important pathogens include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enteric gram-negative bacilli, particularly after urinary tract instrumentation.",
"     </li>",
"     <li>",
"      Pseudomonas aeruginosa and Candida spp are frequently associated with intravascular access sepsis or injection drug use [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11671?source=see_link\">",
"       \"Candida osteoarticular infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Groups B and G hemolytic streptococci, especially in patients with diabetes mellitus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9621?source=see_link\">",
"       \"Group B streptococcus: Virulence factors and pathogenic mechanisms\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27080?source=see_link\">",
"       \"Group C and group G streptococcal infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tuberculous infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"       \"Skeletal tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Geography also influences the organisms associated with vertebral osteomyelitis. Brucella melitensis is an important pathogen in the Middle East and Mediterranean countries; Burkholderia pseudomallei (melioidosis) should always be considered as a potential pathogen in patients from periequatorial regions; and Salmonella and Entamoeba histolytica are occasional causes in regions such as Africa or South America. In addition, the presence of immunosuppression has an effect on the likely pathogens causing vertebral osteomyelitis in an individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical manifestation of vertebral osteomyelitis is back or neck pain, sometimes in patients who have known or suspected degenerative spinal disease. Since back pain is a common complaint leading to physician visits, it is essential that the diagnosis of vertebral osteomyelitis be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no diagnostic characteristic to the pain of vertebral osteomyelitis. Spinal pain usually begins insidiously and progressively worsens over several weeks and sometimes over several months. In a series of 64 patients with hematogenous vertebral osteomyelitis, for example, the mean duration of symptoms was 48 &plusmn; 40 days [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/15\">",
"     15",
"    </a>",
"    ]. The pain is often worse at night although, at least initially, it may be relieved by bed rest. One caveat is that pain may be absent in patients with paraplegia.",
"   </p>",
"   <p>",
"    Patients whose infections extend posteriorly into the epidural space may present with clinical features of an epidural abscess. This often consists of a typical sequence of back pain, which is often focal and severe, then root pain, then motor weakness and sensory changes, and eventually paralysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=see_link\">",
"     \"Epidural abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever is an inconsistent finding. A 1979 review noted a frequency of 52 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/2\">",
"     2",
"    </a>",
"    ], while a somewhat lower rate has been noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local tenderness to gentle spinal percussion is the most reliable clinical sign; this is frequently accompanied by reduced back mobility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protective spasm of nearby muscles. Rarely, there is a visible mass or even spinal deformity.",
"   </p>",
"   <p>",
"    The physical examination should include palpation for a distended bladder, a check for the signs of psoas abscess (eg, flank pain and limitations of and pain on hip movement), and a careful neurologic assessment of the lower limbs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The leukocyte count may be elevated or normal, but more than 80 percent of patients have elevations in the erythrocyte sedimentation rate (ESR), which can exceed 100",
"    <span class=\"nowrap\">",
"     mm/h,",
"    </span>",
"    and in the acute phase reactant, C-reactive protein (CRP) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/4,17,18\">",
"     4,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ESR, if elevated, may have utility in following the efficacy of therapy. This was illustrated in a retrospective study of 44 such patients; those without a significant decline in the ESR during the first month of therapy were more likely to fail medical therapy (9 of 18 cases compared to 3 of 26 cases with a &gt;50 percent fall in ESR) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/17\">",
"     17",
"    </a>",
"    ]. However, a rapid decline was not common: the ESR either rose or failed to decline during the first two weeks of treatment in 19 of 32 patients who were ultimately cured with medical therapy. Similar findings have been reported by others [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/19\">",
"     19",
"    </a>",
"    ]. Because CRP normalizes more rapidly than the ESR after successful treatment of spinal infections and after uncomplicated spinal fusion surgery, some experts prefer to follow CRP levels rather than the ESR during and after treatment of vertebral osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis in patients who present with back pain accompanied by fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacteremia, include an infection in a site other than the back with an incidental noninfectious spinal disease identified when imaging studies of the spine are performed. Noninfectious spine conditions include a compression fracture, metastatic spinal lesions, or herniated disk or degenerative spinal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of vertebral osteomyelitis is difficult in some patients, and relatively easy and straightforward in others. It is not uncommon for the pain to be erroneously attributed to distant or recent minor trauma or other causes, particularly in patients who have no risk factors for osteomyelitis such as injection drug use, endocarditis, prior spinal surgery, diabetes, corticosteroid therapy, or other immunocompromised state. In a report of ten patients with what has been called spontaneous vertebral osteomyelitis, all had been misdiagnosed and five had undergone unnecessary surgery or radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vertebral osteomyelitis is usually first suspected on the basis of clinical features and abnormal radiographic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radionuclide scanning findings; it is then usually confirmed by aspiration of the infected intervertebral disc space (discitis) or vertebral bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures are positive in up to 50 to 70 percent of patients with vertebral osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. They should be obtained in all patients with suspected vertebral osteomyelitis because positive blood cultures may obviate the need for invasive diagnostic tests. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Suggested diagnostic approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Bone radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs are often normal when obtained in the early phases of infection. Typical findings in vertebral osteomyelitis consist of destructive changes of two contiguous vertebral bodies with collapse of the intervening disc space. However, bone destruction may not be apparent for two to three weeks or more after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/14,21\">",
"     14,21",
"    </a>",
"    ]. Rarely, the infection is confined to a single vertebra and produces collapse of the vertebral body that mimics an ordinary vertebral compression fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) shows typical or suggestive changes of vertebral osteomyelitis before such changes are apparent on plain films. CT scanning also is useful for detecting the presence of bony sequestra or involucra, adjacent soft tissue abscesses, and in finding and localizing the optimal approach for a biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/20\">",
"     20",
"    </a>",
"    ]. However, subtle abnormalities detected by CT scanning such as end plate irregularities may not be specific for osteomyelitis and early destructive changes may be missed by this imaging technique. Plain CT also has a high false negative rate for epidural abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the most sensitive radiologic technique to detect vertebral osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/20\">",
"     20",
"    </a>",
"    ]. MRI is also superior to CT scanning for detection of epidural abscesses but cannot be used in patients with certain metal implants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=see_link\">",
"     \"Epidural abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI abnormalities consistent with osteomyelitis can be seen before plain films become abnormal. In a review of 103 patients, MRI showed either typical or suggestive changes of osteomyelitis in 91 percent of patients with symptoms of less than two weeks' duration and in 96 percent of those with symptoms of more than two weeks' duration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical MRI findings in vertebral osteomyelitis include (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87174 \" href=\"UTD.htm?12/39/12919\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On T1-weighted images, decreased signal intensity in the vertebral bodies and disc and loss of endplate definition.",
"     </li>",
"     <li>",
"      On T2-weighted images, increased disc and less often vertebral body signal intensity.",
"     </li>",
"     <li>",
"      Contrast enhancement of the vertebral body and disc. In addition, ring enhancement of paraspinal and epidural processes correlates with abscess formation, whereas homogeneous enhancement correlates with phlegmon formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    False-negative MRI findings have been reported in patients with vertebral osteomyelitis and epidural abscess, especially in those with concurrent meningitis or with long linear abscesses lacking discrete margins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/27\">",
"     27",
"    </a>",
"    ]. On the other hand, false positive results can occur with bone infarction or fracture.",
"   </p>",
"   <p>",
"    The role of follow-up MRI imaging is discussed below. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Role of follow-up imaging studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Radionuclide scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioisotope studies may be a useful adjunct to diagnosis, when radiographic changes on plain films or CT scans are either absent or equivocal and the suspicion for osteomyelitis is high. Such studies are relatively sensitive but their specificity for infection is low.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Labeled-leukocyte scans are rarely useful for the diagnosis of vertebral osteomyelitis because abnormalities typically manifest as a nonspecific photopenic defect with a reduced uptake of isotope [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Three-phase bone scintigraphy using labeled technetium is a relatively sensitive and specific test, but it may produce false-positive results in patients with noninfectious disorders such as fracture. False-negative results also can occur early in infection or in cases in which bone infarction accompanies bone infection.",
"     </li>",
"     <li>",
"      Gallium imaging is the most sensitive and specific radionuclide scanning technique for vertebral osteomyelitis. A typical positive test reveals intense uptake in two adjacent vertebrae with loss of the intervening disc space. In a series of 41 patients with suspected vertebral osteomyelitis, increased gallium uptake was detected in all of the 39 patients with biopsy-proven osteomyelitis; subsequent biopsy showed only degenerative changes in two patients with negative gallium scans [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is generally needed to confirm the clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic suspicion of vertebral osteomyelitis. Biopsy material may be obtained via an open procedure or needle biopsy by CT guidance. In one study of 92 patients with vertebral osteomyelitis who underwent biopsy, open biopsies had a higher microbiologic yield than needle biopsies (91 versus 53 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The samples should be sent for aerobic, anaerobic, mycobacterial, and fungal cultures and pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/14\">",
"     14",
"    </a>",
"    ]. The sensitivity (measured by yield of positive cultures or Gram stain of aspirated material) has varied in different small cases series from a low of 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/31\">",
"     31",
"    </a>",
"    ] to a high of 73 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/11,32\">",
"     11,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amplification-based DNA analysis of aspirated disc material correlated well with traditional culture methods in a study involving 19 patients with infectious discitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/33\">",
"     33",
"    </a>",
"    ]. A pathogen was identified in all patients with PCR techniques compared to only 14 with standard microbiologic methods. We believe that such techniques are best reserved for the minority of patients in whom repeat aspiration is undertaken after routine microbiologic culture methods have failed to reveal a diagnosis. Contamination with skin flora is a potential problem with DNA-based diagnostic methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Suggested diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation of most patients with suspected vertebral osteomyelitis includes a physical examination, ESR, blood cultures, and plain radiographs of the painful portion of the spine. Patients should be questioned about possible predisposing factors or events, including underlying illnesses, hospitalization, invasive procedures, injection drug use, and travel.",
"   </p>",
"   <p>",
"    If localized spinal tenderness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevated ESR is present and if plain films are negative, we usually obtain an MRI scan to further evaluate the possibility of osteomyelitis. Radionuclide scanning is performed only in selected patients with these clinical findings if an MRI cannot be performed. If any of these imaging tests show changes typical or suggestive of vertebral osteomyelitis, we usually proceed to a CT-guided needle biopsy of the affected bone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/14\">",
"     14",
"    </a>",
"    ]. The specimens should be sent for histologic examination and for aerobic and anaerobic bacterial, fungal, and mycobacterial cultures.",
"   </p>",
"   <p>",
"    A needle biopsy may not be necessary in patients with clinical and radiographic findings typical of vertebral osteomyelitis and positive blood cultures with a likely pathogen (such as S. aureus, a gram-negative enteric rod, or P. aeruginosa). One concern with this approach is that the organism isolated from blood cultures does not always correlate with culture results from needle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If cultures of blood and the needle aspirate are negative and the clinical suspicion for vertebral osteomyelitis remains high on the basis of clinical and radiographic findings, we advocate performing a second biopsy. If this specimen is also nondiagnostic, we usually initiate empiric therapy directed against common gram-positive (especially S. aureus), and gram-negative bacterial pathogens (see below). If such therapy does not result in objective clinical improvement in three to four weeks, a third percutaneous needle biopsy or an open surgical biopsy should be performed. Other specialists suggest that, if the first set of cultures is negative, open biopsy be considered before starting antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Antimicrobial therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Such decisions must consider the location of the infection, the underlying health of the patient, and experience of the local surgeons. As an example, open biopsy of the thoracic spine may require thoracotomy and open biopsy of the cervical spine may have equally complex ramifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Evaluation for endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evaluation of potential concurrent infectious endocarditis (IE) may be warranted in select patients. A retrospective review of 91 cases of vertebral osteomyelitis (excluding tuberculosis, brucellosis, culture-negative, and postsurgical cases) identified 28 patients (31 percent) with IE [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/34\">",
"     34",
"    </a>",
"    ]. When patients with and without IE were compared, the following risk factors were significantly associated with coincident IE:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Predisposing heart condition",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Positive blood cultures",
"     </li>",
"     <li>",
"      Infection due to gram-positive organisms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vertebral osteomyelitis without IE was more likely in patients with a urinary tract presumed source of infection and with infection due to gram-negative microorganisms. The incidence of coincident disease reported in this study may have been affected by referral bias as the study was performed at a tertiary referral center.",
"   </p>",
"   <p>",
"    Although duration of therapy for vertebral osteomyelitis (at least six weeks) is adequate to treat IE, the importance of identifying coexisting IE is that patients with IE require follow-up evaluation for possible valvular damage and prophylactic antibiotics for procedures likely to produce bacteremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These findings suggest that patients with vertebral osteomyelitis who are at high risk for IE (as defined by the risk factors above) should be evaluated with echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnostic approach to infective endocarditis\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PITFALLS IN DIAGNOSIS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following caveats apply to the diagnosis and management of vertebral osteomyelitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Back pain due to vertebral osteomyelitis may initially respond to bed rest and conservative measures, leading to the erroneous assumption that strain or other noninfectious cause of back pain is present.",
"     </li>",
"     <li>",
"      A history of degenerative spinal disease or recent trauma may obscure or delay the true diagnosis.",
"     </li>",
"     <li>",
"      Radiographic studies, including magnetic resonance imaging (MRI) and computed tomography (CT), can be falsely negative, particularly if performed early in the course of illness [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Plain films, CT scans, and MRI studies may worsen for several weeks (and occasionally even longer) after the initiation of therapy that will be ultimately successful [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vertebral osteomyelitis rarely occurs without characteristic involvement of the intervertebral disc. In cases where the disc is spared, an erroneous diagnosis of malignancy or compression fracture may be made [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy and in rare cases surgery should lead to a good outcome in most patients with vertebral osteomyelitis. Early diagnosis and careful follow-up for signs of soft tissue extension, paraspinal abscess, and cord compression are important. The response to therapy is best assessed by evaluating ongoing symptoms and serially measuring the C-reactive protein (CRP)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erythrocyte sedimentation rate (ESR) rather than repeating imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of vertebral osteomyelitis respond to antimicrobial therapy. However, surgery is necessary in some patients.",
"   </p>",
"   <p>",
"    No randomized controlled studies have evaluated antibiotic regimens for vertebral osteomyelitis. The antimicrobial regimen is based on blood or biopsy stain and culture results. The decision of whether to begin or withhold empiric antimicrobial therapy pending results of cultures has to be made on an individual basis. Because therapy for this infection is prolonged and because the biopsy may need to be repeated if negative (eg, due to sampling error), we generally advise withholding therapy until cultures return in patients who are clinically stable. In one retrospective cohort study of 92 patients with vertebral osteomyelitis who underwent biopsy, prebiopsy antibiotic therapy did not diminish the yield of culture results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If cultures of blood and a repeat needle aspirate are negative and the clinical suspicion for vertebral osteomyelitis remains high on the basis of clinical and radiographic findings, we initiate empiric therapy directed against the most likely organisms to cause infection in this setting (eg, staphylococci, streptococci, and gram-negative bacilli).",
"   </p>",
"   <p>",
"    We routinely give parenteral antibiotics, with the exception of documented infection due to fluoroquinolone-susceptible gram-negative rods. Oral fluoroquinolone therapy can be used early in the treatment in gram-negative bacilli osteomyelitis if the organism is highly susceptible on the basis of in vitro susceptibility testing, and if compliance with oral therapy can be monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link\">",
"     \"Fluoroquinolones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Pathogen directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend parenteral antibiotics directed against the isolated pathogen if the culture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Gram stain of the CT-guided needle biopsy is positive, guided by the results of susceptibility testing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staphylococcal spp &mdash; If the identified organism is found to be a staphylococcus that is methicillin-susceptible, then we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      (1.5 to 2 g IV every four hours); if methicillin-resistant, then we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per 24 hours in two equally divided doses, not to exceed 2 g per 24 hours unless concentrations in serum are inappropriately low).",
"     </li>",
"     <li>",
"      Streptococcal spp &mdash; If the streptococci is fully sensitive to penicillin (MIC &lt;0.12",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      we recommend treatment with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (1 to 2 g IV every 24 hours) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (12 to 18 million",
"      <span class=\"nowrap\">",
"       U/day",
"      </span>",
"      by continuous infusion [for outpatients] or in six divided daily doses [for inpatients]).",
"      <br/>",
"      <br/>",
"      If the streptococcus has intermediate susceptibility to penicillin (MIC between 0.12 and 0.5",
"      <span class=\"nowrap\">",
"       mcg/mL),",
"      </span>",
"      we typically treat with ceftriaxone or higher doses of penicillin (24 million",
"      <span class=\"nowrap\">",
"       U/day",
"      </span>",
"      per continuous infusion or in six divided daily doses). Patients with intermediate or fully resistant streptococci should be treated in collaboration with a specialist in infectious diseases or microbiology. Specialized in vitro testing may be needed to select an appropriate antibiotic regimen for infections caused by fully resistant streptococci.",
"     </li>",
"     <li>",
"      Gram-negative bacilli &mdash; Choice of a specific agent for empiric therapy of gram-negative bacilli should be based on knowledge of the prevailing pathogens (and susceptibility patterns) within the healthcare setting. Initial treatment with one of the following is appropriate:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Third generation cephalosporin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      1 to 2 g IV daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      2 g IV every 8 hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      2 g IV every six hours)",
"     </li>",
"     <li>",
"      Fourth generation cephalosporin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      2 g IV every 12 hours)",
"     </li>",
"     <li>",
"      Fluoroquinolone (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      400 mg IV every 12 hours or 500 to 750 mg orally every 12 hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Culture-negative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend treatment in patients with negative cultures and Gram stain despite repeat biopsies be based on the most likely organisms to cause infection. An appropriate empiric regimen consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per 24 hours in two equally divided doses, not to exceed 2 g per 24 hours unless concentrations in serum are inappropriately low)",
"    <strong>",
"     plus",
"    </strong>",
"    one of the following:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    (2 g IV every six hours),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    (1 to 2 g IV every 8 to 12 hours),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 to 2 g IV daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    (2 g IV every 12 hours), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (400 mg IV every 12 hours or 500 to 750 mg orally twice daily).",
"   </p>",
"   <p>",
"    Anaerobes are uncommon pathogens in patients with vertebral osteomyelitis and we do not routinely add anaerobic coverage to initial empiric therapy. Such coverage, which can be provided by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"     ticarcillin-clavulanate",
"    </a>",
"    (3.1 g IV every six hours) or by adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg IV every six hours) to combination therapy, should be given in two settings: if clinical features suggest that the infection may be due to anaerobic organisms (eg, in patients with an intraabdominal abscess) or if the Gram stain is positive but aerobic cultures are negative.",
"   </p>",
"   <p>",
"    If such empiric therapy does not result in objective clinical improvement in three to four weeks, a third percutaneous needle biopsy or an open surgical biopsy should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Switch to oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is a good clinical response to parenteral therapy after several weeks of intravenous therapy, a change to oral therapy can be considered. A switch to an oral agent should only be made if a suitable drug with proven susceptibility to the causative organism is available",
"    <strong>",
"     and",
"    </strong>",
"    if compliance with oral therapy can be assured or carefully monitored. Most patients require parenteral therapy throughout.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized controlled studies have evaluated the duration of antibiotic treatment for vertebral osteomyelitis. The duration is based on small case series and treatment of other deep-seated infections. We routinely treat for a minimum of six weeks. Longer therapy (12 weeks) may be necessary for patients with advanced disease as manifested by extensive bone destruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paravertebral infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Fungal osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of fungal vertebral osteomyelitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11671?source=see_link\">",
"     \"Candida osteoarticular infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Adjunctive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bed rest and opioid analgesics are generally helpful in managing pain after the diagnosis is established. A fitted back brace may provide substantial back relief and allow mobility for patients with severe pain.",
"   </p>",
"   <p>",
"    Early bed rest may be particularly important, especially in lumbar osteomyelitis. When the patient is upright, the whole weight of the upper body is transmitted to the point of active infection. It is our practice to initially put patients with severe pain to bed for at least 10 days using intensive in-bed, non-weight bearing physical therapy and long-acting oral analgesics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Role of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is necessary in a minority of patients with vertebral osteomyelitis. There are three main indications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression of disease despite adequate directed or empiric antimicrobial therapy.",
"     </li>",
"     <li>",
"      Threatened or actual cord compression due to vertebral collapse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      spinal instability.",
"     </li>",
"     <li>",
"      Drainage of epidural or paravertebral abscesses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=see_link\">",
"       \"Epidural abscess\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a report of 42 patients with vertebral osteomyelitis who required surgery, 40 had complete resolution of their deficits with no recurrences following a two-stage procedure that included anterior debridement and strut grafting followed by delayed instrumented posterior fusions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients received an average of 14.4 days of intravenous antibiotics after the anterior debridement and six weeks of intravenous therapy following the posterior instrumentation. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Minimally invasive surgical techniques including thoracoscopy, laparoscopy, percutaneous transpedicular debridement and discectomy, and video-assisted procedures using limited open incisions are used in a minority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If paravertebral or epidural abscess formation is present, CT-guided catheter drainage is usually sufficient. However, open surgical drainage, surgical bone debridements, and interbody fusion (with or without bone grafting and posterior instrumentation) are occasionally required. In addition, single-stage surgical debridement with reconstruction using titanium mesh cages has been successful in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=see_link\">",
"     \"Epidural abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Role of follow-up imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of obtaining imaging studies four to eight weeks after completion of treatment of vertebral osteomyelitis was examined in a retrospective study of 79 patients treated at the Mayo Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/42\">",
"     42",
"    </a>",
"    ]. None of 27 patients who demonstrated improvement in follow-up MR imaging studies had evidence of treatment failure after one year of follow-up. In contrast, 5 of 38 (13 percent) and 4 of 14 (29 percent) whose initial follow-up images showed equivocal changes or worsening failed treatment during long-term follow-up. Only 3 of 52 (6 percent) patients who had an improved clinical status at the end of therapy had late evidence of treatment failure compared with 21 and 25 percent of patients who were judged to have equivocal or worse clinical symptoms at the end of therapy. The authors of this study concluded that follow-up imaging studies were most useful in patients who had equivocal or worse clinical status at the end of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious complication of vertebral osteomyelitis is neurologic impairment secondary to either abscess formation or bony collapse. Most, but not all, patients have gradual improvement in back pain after therapy is begun, and the pain typically disappears after bone fusion occurs. However, back pain can persist. The best way to reduce the morbidity and mortality associated with vertebral osteomyelitis is to limit the time between the onset of symptoms and the initiation of appropriate therapy.",
"   </p>",
"   <p>",
"    The long-term outcome in vertebral osteomyelitis was evaluated in a retrospective analysis of 253 patients in whom the median duration of follow-up was 6.5 years (range 2 days to 38 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/43\">",
"     43",
"    </a>",
"    ]. The majority of patients had bacteremia and were presumed to have hematogenous osteomyelitis. Relapse occurred in 14 percent and residual symptoms occurred in 31 percent. In addition, 11 percent died. Surgery was performed in 109 of the 253 patients (43 percent) and was deemed successful in 79 percent.",
"   </p>",
"   <p>",
"    Independent risk factors for death or residual symptoms included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic compromise at the time of diagnosis (eg, motor weakness, spinal instability, paralysis)",
"     </li>",
"     <li>",
"      Nosocomial acquisition of infection",
"     </li>",
"     <li>",
"      Delay in diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of this study need to be interpreted with caution since cases were collected over a long time period (1950 to 1994), which means that some cases occurred prior to the development of modern imaging and diagnostic techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality from vertebral osteomyelitis in the antibiotic era has been less than 5 percent, and the rate of residual neurologic deficits among survivors should be less than 7 percent. In a more modern report of 42 patients with vertebral osteomyelitis who required surgery, two (5 percent) died and all of the 40 survivors had complete resolution of their deficits with no recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22985/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Pathogenesis and microbiology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vertebral osteomyelitis occurs by three basic routes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hematogenous spread from a distant site or focus of infection",
"     </li>",
"     <li>",
"      Direct inoculation from trauma or spinal surgery",
"     </li>",
"     <li>",
"      Contiguous spread from adjacent soft tissue infection",
"      <br/>",
"      <br/>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematogenous spread is by far the most common cause of vertebral osteomyelitis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hematogenous spread'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important infecting organism in vertebral osteomyelitis is Staphylococcus aureus, accounting for more than 50 percent of cases. Other pathogens include enteric gram-negative bacilli, Candida spp, Pseudomonas aeruginosa, Groups B and G streptococci, and Mycobacterium tuberculosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major clinical manifestation of vertebral osteomyelitis is back or neck pain. Fever occurs inconsistently. The most common clinical finding is local tenderness to percussion over the involved posterior spinous processes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common laboratory abnormalities are an elevated erythrocyte sedimentation rate (ESR), which can exceed 100",
"      <span class=\"nowrap\">",
"       mm/h,",
"      </span>",
"      and C-reactive protein (CRP). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of vertebral osteomyelitis is difficult in some patients, and relatively easy and straightforward in others. Vertebral osteomyelitis is usually first suspected on the basis of clinical features and abnormal imaging studies; it can then be confirmed by aspiration of the infected intervertebral disc space (discitis) or vertebral bone. Blood cultures are positive in up to 50 to 70 percent of patients. Every effort should be made to identify the pathogen(s) before starting antimicrobial treatment. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) is the most sensitive radiologic technique to detect vertebral osteomyelitis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the following diagnostic approach in patients with suspected vertebral osteomyelitis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Initial evaluation includes a physical examination, ESR",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CRP, blood cultures, and plain radiographs of the painful portion of the spine.",
"     </li>",
"     <li>",
"      If localized spinal tenderness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an elevated ESR or CRP is present and if plain films are negative, obtain an MRI scan to further evaluate the possibility of osteomyelitis.",
"     </li>",
"     <li>",
"      If imaging tests show changes typical or suggestive of vertebral osteomyelitis, proceed to a CT-guided needle biopsy of the affected bone. The specimens should be sent for histologic examination and for aerobic and anaerobic bacterial, fungal, and mycobacterial cultures and stains.",
"     </li>",
"     <li>",
"      A needle biopsy may not be necessary in patients with clinical and radiographic findings typical of vertebral osteomyelitis and positive blood cultures with a likely pathogen.",
"     </li>",
"     <li>",
"      If cultures of blood and the needle aspirate are negative and the clinical suspicion for vertebral osteomyelitis remains high on the basis of clinical and radiographic findings, we perform a second biopsy.",
"     </li>",
"     <li>",
"      If the second specimen is also nondiagnostic, we initiate empiric therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of potential concurrent infectious endocarditis (IE) may be warranted in select patients. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Evaluation for endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most cases of vertebral osteomyelitis respond to antimicrobial therapy. However, surgery is necessary in some patients. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend, in stable patients, to hold antibiotics until results of blood cultures and needle aspirate are available. (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the culture",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Gram stain of the CT-guided needle biopsy is positive, antibiotic therapy should be guided by the results of susceptibility testing. For most patients we recommend treatment with parenteral antibiotics (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Pathogen directed therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with negative cultures and Gram stains despite repeat biopsies and in unstable patients, we recommend empiric treatment based on the most likely organisms to cause infection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). An appropriate empiric regimen consists of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per 24 hours in two equally divided doses, not to exceed 2 g per 24 hours unless concentrations in serum are inappropriately low)",
"      <strong>",
"       plus",
"      </strong>",
"      one of the following:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (2 g IV every six hours),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      (1 to 2 g IV every eight to 12 hours),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (1 to 2 g IV daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      (2 g IV every 12 hours), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (400 mg IV every 12 hours or 500 to 750 mg orally twice daily). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Culture-negative therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If treatment in patients in whom empiric therapy is initiated does not result in objective clinical improvement in three to four weeks, we typically request a third percutaneous needle biopsy or an open surgical biopsy be performed. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Culture-negative therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We routinely treat for a minimum of six weeks. Longer therapy (12 weeks) may be necessary for patients with advanced disease. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Duration of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery is necessary in a minority of patients with vertebral osteomyelitis. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Role of surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/1\">",
"      Kulowski J. Pyogenic vertebral osteomyelitis of the spine: An analysis and discussion of 102 cases. J Bone Joint Surg 1936; 1:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/2\">",
"      Sapico FL, Montgomerie JZ. Pyogenic vertebral osteomyelitis: report of nine cases and review of the literature. Rev Infect Dis 1979; 1:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/3\">",
"      Digby JM, Kersley JB. Pyogenic non-tuberculous spinal infection: an analysis of thirty cases. J Bone Joint Surg Br 1979; 61:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/4\">",
"      Beronius M, Bergman B, Andersson R. Vertebral osteomyelitis in G&ouml;teborg, Sweden: a retrospective study of patients during 1990-95. Scand J Infect Dis 2001; 33:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/5\">",
"      Batson OV. THE FUNCTION OF THE VERTEBRAL VEINS AND THEIR ROLE IN THE SPREAD OF METASTASES. Ann Surg 1940; 112:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/6\">",
"      HENRIQUES CQ. Osteomyelitis as a complication in urology; with special reference to the paravertebral venous plexus. Br J Surg 1958; 46:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/7\">",
"      Cahill DW, Love LC, Rechtine GR. Pyogenic osteomyelitis of the spine in the elderly. J Neurosurg 1991; 74:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/8\">",
"      McHenry MC, Rehm SJ, Krajewski LP, et al. Vertebral osteomyelitis and aortic lesions: case report and review. Rev Infect Dis 1991; 13:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/9\">",
"      Falagas ME, Bliziotis IA, Mavrogenis AF, Papagelopoulos PJ. Spondylodiscitis after facet joint steroid injection: a case report and review of the literature. Scand J Infect Dis 2006; 38:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/10\">",
"      Hooten WM, Mizerak A, Carns PE, Huntoon MA. Discitis after lumbar epidural corticosteroid injection: a case report and analysis of the case report literature. Pain Med 2006; 7:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/11\">",
"      Torda AJ, Gottlieb T, Bradbury R. Pyogenic vertebral osteomyelitis: analysis of 20 cases and review. Clin Infect Dis 1995; 20:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/12\">",
"      Bass SN, Ailani RK, Shekar R, Gerblich AA. Pyogenic vertebral osteomyelitis presenting as exudative pleural effusion: a series of five cases. Chest 1998; 114:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/13\">",
"      Michel-Bat&ocirc;t C, Dintinger H, Blum A, et al. A particular form of septic arthritis: septic arthritis of facet joint. Joint Bone Spine 2008; 75:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/14\">",
"      Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/15\">",
"      Nolla JM, Ariza J, G&oacute;mez-Vaquero C, et al. Spontaneous pyogenic vertebral osteomyelitis in nondrug users. Semin Arthritis Rheum 2002; 31:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/16\">",
"      Patzakis MJ, Rao S, Wilkins J, et al. Analysis of 61 cases of vertebral osteomyelitis. Clin Orthop Relat Res 1991; :178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/17\">",
"      Carragee EJ, Kim D, van der Vlugt T, Vittum D. The clinical use of erythrocyte sedimentation rate in pyogenic vertebral osteomyelitis. Spine (Phila Pa 1976) 1997; 22:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/18\">",
"      Unkila-Kallio L, Kallio MJ, Eskola J, Peltola H. Serum C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in acute hematogenous osteomyelitis of children. Pediatrics 1994; 93:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/19\">",
"      Khan MH, Smith PN, Rao N, Donaldson WF. Serum C-reactive protein levels correlate with clinical response in patients treated with antibiotics for wound infections after spinal surgery. Spine J 2006; 6:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/20\">",
"      An HS, Seldomridge JA. Spinal infections: diagnostic tests and imaging studies. Clin Orthop Relat Res 2006; 444:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/21\">",
"      Gold RH, Hawkins RA, Katz RD. Bacterial osteomyelitis: findings on plain radiography, CT, MR, and scintigraphy. AJR Am J Roentgenol 1991; 157:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/22\">",
"      Abe E, Yan K, Okada K. Pyogenic vertebral osteomyelitis presenting as single spinal compression fracture: a case report and review of the literature. Spinal Cord 2000; 38:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/23\">",
"      Markus HS. Haematogenous osteomyelitis in the adult: a clinical and epidemiological study. Q J Med 1989; 71:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/24\">",
"      Carragee EJ. The clinical use of magnetic resonance imaging in pyogenic vertebral osteomyelitis. Spine (Phila Pa 1976) 1997; 22:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/25\">",
"      Dagirmanjian A, Schils J, McHenry M, Modic MT. MR imaging of vertebral osteomyelitis revisited. AJR Am J Roentgenol 1996; 167:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/26\">",
"      Ledermann HP, Schweitzer ME, Morrison WB, Carrino JA. MR imaging findings in spinal infections: rules or myths? Radiology 2003; 228:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/27\">",
"      Post MJ, Quencer RM, Montalvo BM, et al. Spinal infection: evaluation with MR imaging and intraoperative US. Radiology 1988; 169:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/28\">",
"      Palestro CJ, Torres MA. Radionuclide imaging in orthopedic infections. Semin Nucl Med 1997; 27:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/29\">",
"      Hadjipavlou AG, Cesani-Vazquez F, Villaneuva-Meyer J, et al. The effectiveness of gallium citrate Ga 67 radionuclide imaging in vertebral osteomyelitis revisited. Am J Orthop (Belle Mead NJ) 1998; 27:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/30\">",
"      Marschall J, Bhavan KP, Olsen MA, et al. The impact of prebiopsy antibiotics on pathogen recovery in hematogenous vertebral osteomyelitis. Clin Infect Dis 2011; 52:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/31\">",
"      Rawlings CE 3rd, Wilkins RH, Gallis HA, et al. Postoperative intervertebral disc space infection. Neurosurgery 1983; 13:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/32\">",
"      McGahan JP, Dublin AB. Evaluation of spinal infections by plain radiographs, computed tomography, intrathecal metrizamide, and CT-guided biopsy. Diagn Imaging Clin Med 1985; 54:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/33\">",
"      Lecouvet F, Irenge L, Vandercam B, et al. The etiologic diagnosis of infectious discitis is improved by amplification-based DNA analysis. Arthritis Rheum 2004; 50:2985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/34\">",
"      Pigrau C, Almirante B, Flores X, et al. Spontaneous pyogenic vertebral osteomyelitis and endocarditis: incidence, risk factors, and outcome. Am J Med 2005; 118:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/35\">",
"      Kayani I, Kamani I, Syed I, et al. Vertebral osteomyelitis without disc involvement. Clin Radiol 2004; 59:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/36\">",
"      Gentry LO. Oral antimicrobial therapy for osteomyelitis. Ann Intern Med 1991; 114:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/37\">",
"      Dimar JR, Carreon LY, Glassman SD, et al. Treatment of pyogenic vertebral osteomyelitis with anterior debridement and fusion followed by delayed posterior spinal fusion. Spine (Phila Pa 1976) 2004; 29:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/38\">",
"      Parker LM, McAfee PC, Fedder IL, et al. Minimally invasive surgical techniques to treat spine infections. Orthop Clin North Am 1996; 27:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/39\">",
"      M&uuml;ckley T, Sch&uuml;tz T, Schmidt MH, et al. The role of thoracoscopic spinal surgery in the management of pyogenic vertebral osteomyelitis. Spine (Phila Pa 1976) 2004; 29:E227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/40\">",
"      Hadjipavlou AG, Crow WN, Borowski A, et al. Percutaneous transpedicular discectomy and drainage in pyogenic spondylodiscitis. Am J Orthop (Belle Mead NJ) 1998; 27:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/41\">",
"      Kuklo TR, Potter BK, Bell RS, et al. Single-stage treatment of pyogenic spinal infection with titanium mesh cages. J Spinal Disord Tech 2006; 19:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/42\">",
"      Kowalski TJ, Berbari EF, Huddleston PM, et al. Do follow-up imaging examinations provide useful prognostic information in patients with spine infection? Clin Infect Dis 2006; 43:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22985/abstract/43\">",
"      McHenry MC, Easley KA, Locker GA. Vertebral osteomyelitis: long-term outcome for 253 patients from 7 Cleveland-area hospitals. Clin Infect Dis 2002; 34:1342.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7663 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22985=[""].join("\n");
var outline_f22_28_22985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hematogenous spread",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Bone radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Radionuclide scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Suggested diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Evaluation for endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PITFALLS IN DIAGNOSIS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Pathogen directed therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Culture-negative therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Switch to oral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Fungal osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Adjunctive measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Role of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Role of follow-up imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Pathogenesis and microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7663\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7663|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/39/12919\" title=\"diagnostic image 1\">",
"      MRI vertebral osteomyelitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=related_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11671?source=related_link\">",
"      Candida osteoarticular infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=related_link\">",
"      Epidural abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9621?source=related_link\">",
"      Group B streptococcus: Virulence factors and pathogenic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27080?source=related_link\">",
"      Group C and group G streptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39269?source=related_link\">",
"      Pathogenesis of osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=related_link\">",
"      Skeletal tuberculosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_28_22986="Etiology and pathogenesis of myocarditis";
var content_f22_28_22986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and pathogenesis of myocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/28/22986/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/28/22986/contributors\">",
"     Leslie T Cooper, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/28/22986/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/28/22986/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/28/22986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/28/22986/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/28/22986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the current World Health",
"    <span class=\"nowrap\">",
"     Organization/International",
"    </span>",
"    Society and Federation of Cardiology",
"    <span class=\"nowrap\">",
"     (WHO/ISFC)",
"    </span>",
"    definition and classification system, myocarditis is an inflammatory disease of cardiac muscle, diagnosed on endomyocardial biopsy (EMB) by established histological, immunological and immunohistochemical criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/1\">",
"     1",
"    </a>",
"    ]. It can be acute, subacute, or chronic, and there may be either focal or diffuse involvement of the myocardium. In symptomatic patients, the cardiac presentation is frequently one of acute heart failure (HF), although a syndrome mimicking acute myocardial infarction or a tachyarrhythmia, including sudden death, or high-grade heart block may occur. If the epicardium is involved, pericarditis may be associated with pleuritic chest pain and pericardial effusion. Isolated endomyocardial inflammation and fibrosis is seen in L&ouml;ffler's cardiomyopathy, tropical endomyocarditis, hypereosinophilic syndrome, and some adverse drug reactions.",
"   </p>",
"   <p>",
"    The etiology and pathogenesis of myocarditis will be reviewed here. Issues related to the clinical manifestations, diagnosis, natural history, and treatment of myocarditis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=see_link\">",
"     \"Natural history and therapy of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocarditis can be caused by a variety of infectious and noninfectious illnesses (",
"    <a class=\"graphic graphic_table graphicRef56995 \" href=\"UTD.htm?35/10/36014\">",
"     table 1",
"    </a>",
"    ). Among the infectious etiologies, viruses are the presumed most frequent pathogens, but bacteria, fungi, protozoa, and helminths have also been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In developed countries, the most frequently identified viruses were enteroviruses (including coxsackievirus) until the 1990s. Parvovirus B-19 and human herpes virus 6 are the viruses most frequently found.",
"   </p>",
"   <p>",
"    This topic review will focus on viral and hypersensitivity myocarditis. Many of the other causes of myocarditis are discussed in detail elsewhere in UpToDate. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infections such as acute rheumatic fever due to group A streptococci and Chagas disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=see_link\">",
"       \"Epidemiology and pathogenesis of acute rheumatic fever\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Chagas heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autoimmune disorders such as systemic lupus erythematosus, Wegener's granulomatosis, giant cell arteritis, and Takayasu arteritis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. Among patients with lupus, myocarditis has been clinically suspected in approximately 9 percent of cases, including approximately 6 percent with global hypokinesis on echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/4\">",
"       4",
"      </a>",
"      ]. Postmortem studies have suggested that the majority of patients dying of lupus have myocardial involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22456?source=see_link&amp;anchor=H11#H11\">",
"       \"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults\", section on 'Myocarditis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug reactions, including cocaine abuse, that may be overlooked in the differential diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link\">",
"       \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Viral or \"idiopathic\" myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1960s, a link was suggested by seroepidemiologic studies between enteroviral infection, particularly coxsackievirus, and human myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/9\">",
"     9",
"    </a>",
"    ]. Since that time, about 20 viruses have been implicated in human myocarditis (",
"    <a class=\"graphic graphic_table graphicRef56995 \" href=\"UTD.htm?35/10/36014\">",
"     table 1",
"    </a>",
"    ). Furthermore, molecular techniques, such as polymerase chain reaction (PCR) and in situ hybridization, have permitted the direct detection of viral genomes in the hearts of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Pathogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infection is commonly associated with myocarditis in series from Western Europe and North America. The most frequently implicated viruses in the 1980s and 90s were Coxsackie B virus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/10,12-15\">",
"     10,12-15",
"    </a>",
"    ], adenovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/10,15\">",
"     10,15",
"    </a>",
"    ], hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/16\">",
"     16",
"    </a>",
"    ], cytomegalovirus (CMV) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/10,17,18\">",
"     10,17,18",
"    </a>",
"    ], echovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/15\">",
"     15",
"    </a>",
"    ], influenza virus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/10\">",
"     10",
"    </a>",
"    ], Epstein-Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/10,19\">",
"     10,19",
"    </a>",
"    ], and the viruses of childhood exanthematous diseases, including parvovirus B -19 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/2,10,15,20-22\">",
"     2,10,15,20-22",
"    </a>",
"    ]. Human Herpes Virus-6 and Parvovirus B-19 have been the most commonly identified viral genomes in patients with suspected myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/11,23,24\">",
"     11,23,24",
"    </a>",
"    ]. H1N1 influenza A infection is another suspected cause of myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaccinia virus inoculation for protection against smallpox infection results in myocarditis with or without associated pericarditis approximately 1.2 per 10,000 military vaccinees and 6 per 10,000 civilian vaccinees [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In the civilian vaccination program, the incidence of myocarditis with or without associated pericarditis was 1.3 per 10,000 vaccinees if only probable cases are included and 5.5 per 10,000 vaccinees if suspected cases are included [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/28\">",
"     28",
"    </a>",
"    ]. The lower rate in military vaccinees could reflect a highly selected fit population without underlying disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40057?source=see_link&amp;anchor=H20#H20\">",
"     \"Vaccinia virus as the smallpox vaccine\", section on 'Myocarditis and myopericarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relative frequency and type of viral infection as a cause of myocarditis was best evaluated in a large multicenter series of patients with biopsy-proven myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/10\">",
"     10",
"    </a>",
"    ]. The study included 624 patients, age 1 day to 42 years (mean 6.2 years), with acute HF or cardiovascular collapse and an endomyocardial biopsy (EMB) positive for myocarditis by the Dallas criteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Dallas criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cultures were obtained from blood, urine, stool, nasopharynx, and EMB specimens. Serial serologies were obtained, and PCR was performed on blood and cardiac tissue to identify viral nucleic acid. An additional 149 patients had acute HF with a negative EMB and were diagnosed with new onset dilated cardiomyopathy (DCM); 165 control patients with other cardiac disorders were also evaluated. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serology, cultures, and PCR (of cardiac tissue) each detected a viral pathogen in approximately one-third of myocarditis patients; PCR detected a pathogen in 20 percent of DCM patients and only 1.4 percent of controls. Blood samples were positive by PCR in only 1 percent.",
"     </li>",
"     <li>",
"      In case series, parvovirus 19 has been commonly detected by PCR from myocardial biopsy specimens in patients with acute and chronic dilated cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/11,20,29\">",
"       11,20,29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The PCR findings should not be interpreted as providing a definitive diagnosis of the cause of myocarditis cases, since intercurrent or previous viral infection unrelated to the episode of myocarditis cannot be ruled out [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/10\">",
"     10",
"    </a>",
"    ]. Furthermore, among patients who had both positive peripheral cultures and a positive PCR, the results were in agreement in only 76 percent of cases. Despite these concerns, these data suggest that viral pathogens are commonly associated with histologic evidence of myocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Incidence and prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true incidence of idiopathic or \"viral\" myocarditis in the general population is unknown. In early studies, cardiac involvement was suspected to occur in 3.5 to 5 percent of patients during outbreaks of Coxsackievirus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/13,30\">",
"     13,30",
"    </a>",
"    ]. However, there is significant difficulty in establishing a diagnosis of myocarditis because EMB, the diagnostic reference technique, is infrequently used and there is no established noninvasive \"gold standard.\" Furthermore, the sensitivity of EMB, which may reveal a lymphocytic infiltrate, sometimes with evidence of myocardial damage, may be as low as 35 percent by conventional histology (Dallas criteria), although immunohistochemistry and viral PCR have yielded higher sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/10,11,15,19,22,29\">",
"     10,11,15,19,22,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Endomyocardial biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autopsy studies have revealed varying estimates on the incidence of myocarditis that vary with the population studied. In a registry of 1866 young athletes who died suddenly, 6 percent had myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/31\">",
"     31",
"    </a>",
"    ]. A 5 percent prevalence of active myocarditis was reported in a high-risk group of 186 sudden, unexpected medical deaths in children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/32\">",
"     32",
"    </a>",
"    ]. A similar incidence was noted among traumatic deaths in British males aged 18 to 55 years; in this setting, the myocarditis was asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other reports have evaluated the prevalence of myocarditis as a cause of initially unexplained DCM. In a review of 1230 such patients, myocarditis as defined by the Dallas criteria was felt to be responsible in 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/34\">",
"     34",
"    </a>",
"    ], and myocarditis was identified in 10 percent in the over 2200 patients with unexplained HF of less than two years duration in the Myocarditis Treatment Trial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain groups appear to be at increased risk for fulminant viral myocarditis. As an example, children, especially neonates and those who are immunocompromised, may have a severe illness with hemodynamic compromise. In one series, lymphocytic myocarditis was present in 25 of 62 children with dilated cardiomyopathy (40 percent) who underwent cardiac histologic examination within two months of presentation with dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Protective effect of initial immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;By age 30, between 18 and 94 percent of people have antibodies to one or more coxsackie B virus serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. It is likely that this humoral response soon after infection is beneficial, acting to decrease inflammation.",
"   </p>",
"   <p>",
"    Compatible with the beneficial effect of the initial immune response is the observation from the Myocarditis Treatment Trial Investigators that findings consistent with a stronger humoral and cellular immune response were associated with less severe initial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/35\">",
"     35",
"    </a>",
"    ]. Supporting this concept, immune deficient mice develop a severe myocarditis between 7 and 14 days after inoculation with a high subsequent mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the factors that may be protective in the initial immune response are regulatory T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/41\">",
"     41",
"    </a>",
"    ], natural killer (NK) cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/42\">",
"     42",
"    </a>",
"    ], nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/43\">",
"     43",
"    </a>",
"    ], and interferon beta and interferon gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. In a transgenic mouse model in which the pancreatic beta cells express interferon gamma, the spread of an infecting virus is reduced, and infection with coxsackievirus B3 does not produce myocarditis as it does in normal mice [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/44\">",
"     44",
"    </a>",
"    ]. In a mouse strain lacking the interferon beta gene, susceptibility to coxsackievirus B3 is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Role of cytokines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These data, which come almost entirely from animal models, suggest the importance of reducing the level of viremia early during infection. If, however, the initial immune response is insufficient, persisting and possibly replication deficient viruses may drive an adverse autoimmune immune response or directly cause myocyte damage (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Autoimmune mechanisms'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Giant cell myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic giant cell myocarditis is a rare, severe, virus-negative, and frequently fatal type of autoimmune myocarditis that may respond to immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/47\">",
"     47",
"    </a>",
"    ]. In an animal model, a disorder similar to giant cell myocarditis was induced by immunization with cardiac myosin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/48\">",
"     48",
"    </a>",
"    ]. In this model, myocardial damage is primarily mediated by T lymphocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=see_link&amp;anchor=H9#H9\">",
"     \"Natural history and therapy of myocarditis in adults\", section on 'Giant cell myocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hypersensitivity myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity myocarditis (HSM, a form of eosinophilic myocarditis) is an autoimmune reaction in the heart that is often drug-related and is usually characterized by acute rash, fever, peripheral eosinophilia, and ECG abnormalities such as nonspecific ST segment changes or infarct patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, some patients present with sudden death or rapidly progressive HF. The true incidence of HSM is unknown. One estimate comes from an autopsy study, which identified 16 cases in more than three thousand consecutive autopsies (&lt;0.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/50\">",
"     50",
"    </a>",
"    ]. In other series, the prevalence of clinically undetected HSM in explanted hearts ranged from 2.4 to 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSM is usually temporally related to a recently initiated medication. Numerous drugs have been implicated in this drug-induced hypersensitivity syndrome, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , benzodiazepines, and tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. However, HSM does not always develop early in the course of drug use. As an example, patients taking the antipsychotic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    have been reported to develop myocarditis more than two years after the drug was started [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=see_link\">",
"     \"Drug allergy: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Eosinophilic myocarditis has also been seen in 2.4 to 23 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. It is uncertain whether this reaction represents hypersensitivity to the drug itself or a reaction to sodium bisulfite, which is a preservative in many dobutamine preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/56,58\">",
"     56,58",
"    </a>",
"    ]. It has been diagnosed either on EMB or retrospectively after explantation of the native heart. In some cases, tapering or discontinuation of dobutamine infusion has resulted in diminution of the peripheral eosinophilia and histologic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologically, HSM is usually characterized by an interstitial infiltrate with prominent eosinophils, but little myocyte necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/50\">",
"     50",
"    </a>",
"    ]. However, occasional patients with apparent drug hypersensitivity have giant cell myocarditis, granulomatous myocarditis, or necrotizing eosinophilic myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. These disorders can usually be distinguished from hypersensitivity myocarditis only by EMB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=see_link&amp;anchor=H19#H19\">",
"     \"Natural history and therapy of myocarditis in adults\", section on 'Eosinophilic myocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two reports from Italy suggest that celiac disease, which is often clinically unsuspected, accounts for as many as 5 percent of patients with autoimmune myocarditis or idiopathic DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. In one review, 187 consecutive patients with myocarditis were screened for IgA antiendomysial and anti-tissue transglutaminase antibodies; patients with a positive test underwent duodenal endoscopy and biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nine patients (4.8 percent) had celiac disease, compared to 1 of 306 controls (0.3 percent). All nine had anti-heart antibodies in the serum.",
"     </li>",
"     <li>",
"      None of these patients had classic gastrointestinal symptoms of celiac disease (recurrent abdominal pain, diarrhea, and weight loss), but all had iron deficiency anemia that was refractory to iron replacement.",
"     </li>",
"     <li>",
"      Four patients with ventricular arrhythmia and normal cardiac function improved with a gluten-free diet alone. Five patients had progressive HF that failed to respond to more than six months of conventional HF therapy; they were then treated with immunosuppression and a gluten-free diet with a marked improvement in symptoms and left ventricular ejection fraction (LVEF; absolute 18 to 35 percent increase). Although spontaneous improvement is common in patients with myocarditis, these patients had failed a prolonged course of standard therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of 45 children with celiac disease, subclinical systolic dysfunction was present in those children who had high titers of antiendomysial antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/65\">",
"     65",
"    </a>",
"    ]. Autoimmune disorders occur with increased frequency in patients with celiac disease and may be related in part to antigen overload resulting from increased intestinal permeability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although these findings are intriguing, it would be premature to screen all patients with otherwise unexplained myocarditis for celiac disease. However, it is reasonable to ask about a history of gastrointestinal complaints or refractory iron deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Arrhythmogenic RV cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an unusual clinical entity characterized by ventricular arrhythmias and a specific right ventricular (RV) pathology. ARVC is associated with a fatty appearance of the RV free wall; the fibrofatty replacement of the RV myocardium initially produces typical regional RV paradoxical wall motion abnormalities, which later become global, producing RV dilation. The condition is often familial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=see_link\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that some patients with anatomic features of ARVC and no family history of ARVC have myocarditis. In one report, 30 patients without a family history of ARVC with ventricular arrhythmias, evidence of either global or regional RV dysfunction, and diagnostic criteria for ARVC underwent extensive RV and LV biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/66\">",
"     66",
"    </a>",
"    ]. Focal inflammatory infiltrates with necrosis of adjacent myocytes, meeting the Dallas criteria for myocarditis, were present in 21 (70 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic findings compatible with myocarditis can occur in patients with hypertrophic cardiomyopathy and have been associated with rapid deterioration in LV systolic performance; viral genomes have been identified in some of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H16#H16\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'Myocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vaccinia-related myopericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccinia-related clinically suspected myocarditis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pericarditis is a complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41927?source=see_link\">",
"     \"Myopericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     VIRAL MYOCARDITIS AND DILATED CARDIOMYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of viral myocarditis in DCM is an important clinical issue. There are several potential mechanisms by which a viral myocarditis might cause acute or chronic DCM, including direct viral damage or as a result of humoral or cellular immune responses to persistent viral infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Direct viral injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our understanding of the pathogenesis of viral myocarditis comes almost entirely from experimental models of acute coxsackie B virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/68\">",
"     68",
"    </a>",
"    ]. The initial change is myocyte damage in the absence of a cellular immune response. The myocyte injury may be mediated through direct viral toxicity, perforin-mediated cell lysis, and cytokine expression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Intracellular events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral entry into the myocyte is mediated by cell surface receptors. The coxsackie-adenovirus receptor (CAR) is a common receptor for coxsackievirus type B and for adenovirus subgroups A, C, D, E, and F [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. The CAR gene has been localized to chromosome 21q11.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/73\">",
"     73",
"    </a>",
"    ]. With rare exceptions, CAR expression is required for virus entry into cells.",
"   </p>",
"   <p>",
"    The discovery of the CAR receptor raises the possibility of interventional therapy to block CAR in severe cases of coxsackie B virus or adenoviral myocarditis. Coreceptors, including decay-accelerating factor (DAF, CD55) for some coxsackie B virus strains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/74\">",
"     74",
"    </a>",
"    ] and integrins, help determine the efficiency of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. The activity of signaling pathways in cardiac myocytes also may determine susceptibility to coxsackie B myocarditis via effects on viral replication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After entry into the cell through the CAR receptor, the coxsackie B viral genome is translated into structural capsid proteins and several proteases that cleave the viral polyprotein. Viral protease 2A can also cleave certain host proteins, and one mechanism of ongoing myocyte injury is through direct interaction of viral proteins with the cytoskeleton. In a transgenic mouse model, cardiac-restricted expression of protease 2A was sufficient to induce dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protease 2A cleaves dystrophin in vivo, leading to disruption of the dystrophin-glycoprotein complex that is essential for normal cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/79\">",
"     79",
"    </a>",
"    ]. Disruption of the dystrophin-glycoprotein complex is also present in hereditary cardiomyopathies that are related to a dystrophin mutation, such as Duchenne muscular dystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    .) There is more efficient release of the coxsackie B virus from dystrophin-deficient cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/81\">",
"     81",
"    </a>",
"    ]. Thus, dystrophin-deficient mice have greater viral replication and more severe cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Persistent viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the initial immune response plays a protective role against the development of coxsackie B myocarditis. The possible importance of persistent viral replication was illustrated in a study of coxsackie B virus myocarditis in immunocompetent mouse strains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/82\">",
"     82",
"    </a>",
"    ]. Enteroviral RNA was present in acute myocarditis and persisted during the chronic phase of cardiomyopathy.",
"   </p>",
"   <p>",
"    Subsequent studies showed that persistent viral infection was associated with myocardial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. In a transgenic mouse model, for example, the expression of coxsackievirus DNA and the synthesis of viral RNA without formation of infectious viral progeny resulted in typical morphologic features of a human DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/84\">",
"     84",
"    </a>",
"    ]. The isolated myocytes had defective excitation-contraction coupling and a decrease in shortening.",
"   </p>",
"   <p>",
"    Serologic testing, PCR, and probe hybridization in humans have strengthened the connection between persistent myocardial viral infection and the development of DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/10,15,85,86\">",
"     10,15,85,86",
"    </a>",
"    ]. Adenovirus and enterovirus were the most commonly identified viruses in the 1990s. In later studies, parvovirus B-19 and human herpesvirus 6 have been identified more frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/10,11,24,87-91\">",
"     10,11,24,87-91",
"    </a>",
"    ]. In addition, many other viruses have been implicated including HIV, hepatitis C, cytomegalovirus, and varicella [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/11,24,92-95\">",
"     11,24,92-95",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathogen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Indirect support for a pathogenetic role of persistent viral infection was provided in a report cited above of 172 consecutive patients with viral infection of the myocardium by PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/15\">",
"     15",
"    </a>",
"    ]. The LVEF increased in the one-third of patients who had spontaneous clearance of the viral genome on follow-up biopsy at a median of 6.8 months (58 versus 50 percent); in contrast, the LVEF fell in the remaining patients with persistence of the viral genome (54 versus 51 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Enterovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role of persistent enteroviral infection in the development of DCM can be illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the large multicenter series of patients with myocarditis cited above, 149 had a negative biopsy and were diagnosed with new onset DCM [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/10\">",
"       10",
"      </a>",
"      ]. Of these, 12 were positive for enterovirus by PCR (8 percent). Of the 215 controls (no DCM), only one was positive for enterovirus (0.5 percent).",
"     </li>",
"     <li>",
"      In an early series of 45 patients with left ventricular (LV) dysfunction and clinically suspected myocarditis, 22 percent had active enteroviral RNA replication in the myocardium; in comparison, enteroviral RNA was not found in any of the biopsies from 26 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective evaluation of 120 patients with myocarditis or idiopathic DCM, enteroviral RNA sequences were detected in 34 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/90\">",
"       90",
"      </a>",
"      ]. At two years, mortality was significantly increased in the enterovirus-positive patients (25 versus 4 percent in the enterovirus negative group). However, conflicting prognostic data were noted in another report in which mortality at two years in patients with DCM was significantly lower in those who were enterovirus-positive (5 versus 19 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/96\">",
"       96",
"      </a>",
"      ]. In another study, the presence of viral genome was not related to outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Adenovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses, which were frequently present in children with cardiomyopathy in the 1980s and 90s [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/97\">",
"     97",
"    </a>",
"    ], are now less common in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/88\">",
"     88",
"    </a>",
"    ]. A review of 94 adults with idiopathic DCM and 14 controls detected adenoviral type 2 genomic DNA in 13 percent and enteroviral RNA in another 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/87\">",
"     87",
"    </a>",
"    ]. All control samples were negative for both viruses. In two later series, adenovirus was an uncommon pathogen in adult with biopsy-proven myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/11,29\">",
"     11,29",
"    </a>",
"    ] or dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;DCM, occasionally due to myocarditis, develops frequently in advanced HIV infection and is associated with poor prognosis. DCM in HIV may be caused by toxicity of the gp120 protein, adverse reaction to antiviral agents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/98\">",
"     98",
"    </a>",
"    ], or to opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/93,99\">",
"     93,99",
"    </a>",
"    ]. HIV rarely infects cardiac myocytes, and current opinion is that direct HIV cardiotoxicity is uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25226?source=see_link\">",
"     \"Cardiac involvement in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus (HCV) infection has been proposed to be associated with myocarditis and a cardiomyopathy in Japan. A multicenter study of 697 Japanese patients found that HCV antibody was present in 10.6 percent of patients with hypertrophic cardiomyopathy, 6.3 percent with a DCM, and 2.4 percent of normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/94\">",
"     94",
"    </a>",
"    ]. These data suggest that HCV infection may be associated with hypertrophic cardiomyopathy in the Japanese population. Studies to determine the association with HCV infection in populations from North American and Western Europe are lacking. Independent confirmation of these intriguing observations is needed. HCV is not an established cardiotropic virus and it is not known how it might cause a cardiomyopathy. In an animal model, mice that were transgenic for the HCV core gene developed a cardiomyopathy by 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/100\">",
"     100",
"    </a>",
"    ]. This observation suggests a possible pathogenetic role for HCV core protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the above report that evaluated specific viruses as a cause of DCM, one study performed PCR analysis for multiple viral genomes on EMB from 245 patients with idiopathic DCM, none of whom had evidence of active or borderline myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/101\">",
"     101",
"    </a>",
"    ]. Viral genomes were identified in 67 percent, including 27 percent with multiple infections. The most common viruses isolated were parvovirus B19 (51 percent), human herpesvirus-6 (22 percent), enterovirus (9 percent), and Epstein-Barr virus, adenovirus, and cytomegalovirus, each of which was present in &le;2 percent of biopsies. Parvovirus B19 viral genomes have also been associated with idiopathic left ventricular diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Autoimmune mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune mechanisms have been implicated in the pathogenesis of myocarditis, with or without a virus trigger. A subset of patients with biopsy-proven virus-negative myocarditis fulfill the Witebsky-Rose criteria for an autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/1,12,29,47,48,63,64\">",
"     1,12,29,47,48,63,64",
"    </a>",
"    ]. Autoimmune myocarditis may occur in isolation or in the context of extra-cardiac autoimmune disorders, eg, SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/4\">",
"     4",
"    </a>",
"    ]. Autoimmunity may also account for 30 to 40 percent of patients with idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link&amp;anchor=H27#H27\">",
"     \"Causes of dilated cardiomyopathy\", section on 'Autoimmunity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with viral myocarditis, the initial immune response limits the degree of viremia early during infection and protects against myocarditis. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Protective effect of initial immune response'",
"    </a>",
"    above.) If, however, this response is insufficient, the virus may not be eliminated and further myocyte injury may ensue. In addition to direct viral-induced injury, persisting viral genomic fragments that may not be capable of replicating as intact virus may drive an adverse autoimmune response (",
"    <a class=\"graphic graphic_figure graphicRef74290 \" href=\"UTD.htm?2/13/2270\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/103\">",
"     103",
"    </a>",
"    ]. However, in genetically predisposed experimental models and in patients, autoimmune inflammatory heart disease may develop in the absence of a defined previous viral myocarditis.",
"   </p>",
"   <p>",
"    Potentially pathogenic autoantibodies to a variety of cellular components are found in a high percentage of patients with myocarditis and DCM. Autoantigens include alpha and beta cardiac myosin heavy chain, the beta-1 adrenoreceptor, adenine nucleotide translocator (ANT), branched chain keto acid dehydrogenase (BCKD), a variety of sarcolemmal and myolemmal proteins, connective tissue, and extracellular matrix proteins, including laminin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/104-112\">",
"     104-112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of anti-heart antibodies in post-viral autoimmune cases may start with direct viral-induced myocyte damage, with associated release of intracellular proteins. Intracellular antigens may be recognized as foreign because they were previously sequestered from immune surveillance or through molecular mimicry between enteroviral proteins and cardiac proteins. CD4-positive T cells produce myocyte damage by stimulating B cells, cytotoxic cytokines, and cytotoxic CD8+ T cells. The presence of the organ and disease-specific anti-heart autoantibodies of IgG class detected by indirect immunofluorescence on human heart predicts the subsequent development of DCM or left ventricular dysfunction in relatives of patients with DCM from both familial and nonfamilial pedigrees [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The subclass of immunoglobulin may be important in antibody-mediated DCM. In one study of 82 DCM patients, levels of immunoglobulin subclass IgG3, but not IgG1 or IgG2, were elevated compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/114\">",
"     114",
"    </a>",
"    ]. In another report of 76 patients with clinically suspected myocarditis or DCM, there was a significant correlation between the plasma concentration of IgG3 and both hemodynamic and echocardiographic indices of HF severity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of IgG3 may have implications for therapy. Immunoadsorption for the removal of autoantibodies may be performed either with protein A columns (which bind to and remove most IgG, but have a low affinity for IgG3), or with anti-IgG columns (which have specificity for all IgG subclasses). In a trial in which the two types of columns were compared for the monthly treatment of DCM, only the anti-IgG column was associated with significant improvement in cardiac index with the first treatment and at three months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/116\">",
"     116",
"    </a>",
"    ]. The benefit may be increased with more efficient IgG3 removal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/117\">",
"     117",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18809?source=see_link&amp;anchor=H5#H5\">",
"     \"Possibly effective emerging therapies for heart failure\", section on 'Immunoadsorption'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Anti-alpha myosin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential importance of anti-alpha myosin antibodies has been illustrated in several reports. In one study of 53 patients with clinical myocarditis, for example, 17 percent had anti-alpha myosin antibodies, compared to only 4 percent of patients with ischemic heart disease and 2 percent of normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another series of 33 patients, anti-alpha myosin antibodies were present in 17 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/106\">",
"     106",
"    </a>",
"    ]. The antibodies persisted in the majority of patients for at least six months, and did not develop in any patient after the diagnosis of clinical myocarditis had been made. The presence of anti-alpha myosin antibodies was associated with a lower likelihood of improvement in LV systolic and diastolic function at six months compared to patients without these antibodies (no increase in LVEF compared to a 9 percent absolute increase in those without antibodies). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=see_link\">",
"     \"Natural history and therapy of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Anti-beta-1 adrenoceptor antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-beta-1 adrenoceptor antibodies also may play a role in the progression of myocarditis to DCM. In a rabbit model, immunization with sequences of the beta-1 adrenoreceptor results in the production of anti-beta-1 adrenoceptor antibodies and the development of a cardiomyopathy that resembles the human idiopathic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/107\">",
"     107",
"    </a>",
"    ]. These findings appear to be applicable to humans since these autoantibodies can be detected in as many as 38 percent of patients with an idiopathic DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/108,109\">",
"     108,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Removal of anti-beta-1 adrenoreceptor antibodies by selective immunoadsorption has been associated with clinical improvement in patients with idiopathic DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link&amp;anchor=H27#H27\">",
"     \"Causes of dilated cardiomyopathy\", section on 'Autoimmunity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to promoting myocardial injury, one subgroup of these autoantibodies, directed at the second extracellular domain of the beta-1 adrenoceptor, exerts agonist-like activity on the beta adrenoceptor and may play a role in the development of serious ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14615?source=see_link\">",
"     \"Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Autoreactive T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellular immunity also may be involved in the development of a DCM. This was suggested in a study that evaluated myocardial, lymph node, and thymic tissue samples from patients with idiopathic DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/118\">",
"     118",
"    </a>",
"    ]. Overexpression of activated helper and cytotoxic T cells was associated with the presence of coxsackie B virus, which may have been the trigger for a superantigen-mediated immune response (",
"    <a class=\"graphic graphic_figure graphicRef74290 \" href=\"UTD.htm?2/13/2270\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In animal models, cellular immunity is a major mechanism of myocardial injury in post-coxsackie B virus myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. This was illustrated in a study in which genetically susceptible mice were crossed with knockout mice lacking CD4+",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CD8+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/119\">",
"     119",
"    </a>",
"    ]. There was a small decrease in inflammatory infiltrate at 14 days after coxsackie B virus inoculation in mice that lacked CD4+ T cells and a major decrease in mice that lacked both CD4+ and CD8+ T cells. In addition to Th1 and Th2 T cell-mediated myocardial injury, Th17 positive T cells, a T cell subtype that releases IL-17, can mediate autoimmune myocarditis. The Th17 pathway is interesting, since it can be selectively blocked without affecting neutrophil activation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Role of cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the postviral setting, cytokines regulate lymphocyte function in a positive and negative manner and exert a marked influence on the activities of many other cell types engaged in tissue repair and restoration of homeostasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In animal models, progression from myocarditis to a DCM is characterized by a change in cytokine expression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/122\">",
"     122",
"    </a>",
"    ]. Th1 cytokines, including interleukin (IL)-2, interferon gamma, and IL-1-beta, are expressed early in the lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/123\">",
"     123",
"    </a>",
"    ]. The transition to fibrosis and a DCM is heralded by a decrease in the Th1 cytokines and an increase in IL-10, a Th2 cytokine. Gene transfer of IL-10 can protect against autoimmune myocarditis in rats, probably by suppressing the early Th1 type response [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/124\">",
"     124",
"    </a>",
"    ]. However, in one study of patients with myocarditis of unspecified etiology, higher serum levels of IL-10 were associated with greater disease severity and higher mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor necrosis factor-alpha (TNFa) has been implicated in the pathogenesis of myocarditis and DCM in a few animal and human studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/126\">",
"     126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12872?source=see_link\">",
"     \"Nitric oxide, other hormones, cytokines, and chemokines in heart failure\"",
"    </a>",
"    .) Support for the role of TNFa in myocarditis comes from a study of transgenic mice with myocardial expression of TNFa [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/127\">",
"     127",
"    </a>",
"    ]. Production of this cytokine by cardiac myocytes was sufficient to cause severe cardiac disease, including transmural myocarditis and ultimately biventricular fibrosis, chamber dilatation, and LV dysfunction. In addition, there is a strong linear relationship between mortality and TNFa levels in a mouse model of HF due to viral myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In human myocarditis, endomyocardial biopsy specimens show higher levels of a TNFa precursor and the TNFa converting enzyme (TACE), which converts the precursor to its mature form within the myocytes and interstitial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/129\">",
"     129",
"    </a>",
"    ]. TACE and TNFa expression were greater in patients with NYHA class III and IV HF than in those in NYHA class I and II, and increased expression was correlated positively with LV volume and negatively with LV systolic function. However, the clinical importance of TNFa in DCM remains uncertain as randomized trials of anti-TNFa therapy have failed to show benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39221?source=see_link&amp;anchor=H10#H10\">",
"     \"Unproven therapies for chronic systolic heart failure\", section on 'Anti-TNF alpha therapy'",
"    </a>",
"    .) Cytokine expression profiles should be studied in human",
"    <span class=\"nowrap\">",
"     myocarditis/DCM",
"    </span>",
"    of defined viral versus autoimmune pathogenesis prior to translating results from experimental models to the clinical arena.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/14/15586?source=see_link\">",
"       \"Patient information: Myocarditis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral injury and post-viral autoimmune response may be simplified into a three-phase model to characterize the stages of the progression of acute viral infection to DCM; the acute viral myocarditis and autoimmune models of",
"      <span class=\"nowrap\">",
"       myocarditis/DCM",
"      </span>",
"      development are depicted in the figure (",
"      <a class=\"graphic graphic_figure graphicRef74290 \" href=\"UTD.htm?2/13/2270\">",
"       figure 1",
"      </a>",
"      ). The two models do not exclude each other, and may account for the progression from myocarditis to DCM in distinct patient subsets [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/130\">",
"       130",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The first phase is comprised of viral infection with myocyte death within hours of viral cell entry. In this acute stage, myocyte death results from direct viral damage to myocytes and leads to exposure of host proteins to the immune system.",
"     </li>",
"     <li>",
"      The second phase, which rapidly follows, is an innate immune response comprised of altered regulatory T cell function, NK cells, interferon gamma, and nitric oxide.",
"     </li>",
"     <li>",
"      In the third phase, a virus-specific immune response includes antibodies to pathogen. Non-genetically susceptible animals and humans recover with few consequences. In genetically susceptible experimental animals and humans, a breakdown of T cell tolerance to self myocardial autoantigens (eg, cardiac myosin) ensues. This leads to chronic myocardial inflammation,",
"      <span class=\"nowrap\">",
"       necrosis/apoptosis,",
"      </span>",
"      and fibrosis mediated by humoral (Autoantibody-mediated)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cell-mediated organ-specific autoimmunity. These patients may die from arrhythmias or progress onto a phase of DCM with chronic heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In genetically predisposed animals and humans, a long asymptomatic latency period, characterized by ongoing myocardial tissue inflammation and damage, resulting in detectable markers of immune activation in situ (inflammatory cells, increased HLA, and adhesion molecules in the myocardium) and in the periphery (circulating anti-heart autoantibodies, raised cytokine levels). Viral infections or other environmental noxae may act as a second hit or as",
"      <span class=\"nowrap\">",
"       precipitating/accelerating",
"      </span>",
"      factors. The finding that anti-heart autoantibodies precede several years and predict the subsequent development of DCM or left ventricular dysfunction in relatives of patients with DCM from both familial and nonfamilial pedigrees is in keeping with this model [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/131\">",
"       131",
"      </a>",
"      ] and mirrors what happens in other extra-cardiac autoimmune diseases (",
"      <a class=\"graphic graphic_figure graphicRef74290 \" href=\"UTD.htm?2/13/2270\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/28/22986/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/1\">",
"      Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/2\">",
"      Cooper LT Jr. Myocarditis. N Engl J Med 2009; 360:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/3\">",
"      Walsh TJ, Hutchins GM, Bulkley BH, Mendelsohn G. Fungal infections of the heart: analysis of 51 autopsy cases. Am J Cardiol 1980; 45:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/4\">",
"      Wijetunga M, Rockson S. Myocarditis in systemic lupus erythematosus. Am J Med 2002; 113:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/5\">",
"      Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 1999; 74:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/6\">",
"      Pfizenmaier DH, Al Atawi FO, Castillo Y, et al. Predictors of left ventricular dysfunction in patients with Takayasu's or giant cell aortitis. Clin Exp Rheumatol 2004; 22:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/7\">",
"      Virmani R, Robinowitz M, Smialek JE, Smyth DF. Cardiovascular effects of cocaine: an autopsy study of 40 patients. Am Heart J 1988; 115:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/8\">",
"      Kloner RA, Hale S, Alker K, Rezkalla S. The effects of acute and chronic cocaine use on the heart. Circulation 1992; 85:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/9\">",
"      Burch GE, Sun SC, Colcolough HL, et al. Coxsackie B viral myocarditis and valvulitis identified in routine autopsy specimens by immunofluorescent techniques. Am Heart J 1967; 74:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/10\">",
"      Bowles NE, Ni J, Kearney DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003; 42:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/11\">",
"      Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/12\">",
"      Rose NR, Neumann DA, Herskowitz A. Coxsackievirus myocarditis. Adv Intern Med 1992; 37:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/13\">",
"      Grist NR, Bell EJ. Coxsackie viruses and the heart. Am Heart J 1969; 77:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/14\">",
"      Cambridge G, MacArthur CG, Waterson AP, et al. Antibodies to Coxsackie B viruses in congestive cardiomyopathy. Br Heart J 1979; 41:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/15\">",
"      K&uuml;hl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/16\">",
"      Matsumori A, Yutani C, Ikeda Y, et al. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 2000; 80:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/17\">",
"      Sch&ouml;nian U, Crombach M, Maser S, Maisch B. Cytomegalovirus-associated heart muscle disease. Eur Heart J 1995; 16 Suppl O:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/18\">",
"      Cohen JI, Corey GR. Cytomegalovirus infection in the normal host. Medicine (Baltimore) 1985; 64:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/19\">",
"      Chimenti C, Russo A, Pieroni M, et al. Intramyocyte detection of Epstein-Barr virus genome by laser capture microdissection in patients with inflammatory cardiomyopathy. Circulation 2004; 110:3534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/20\">",
"      Breinholt JP, Moulik M, Dreyer WJ, et al. Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. J Heart Lung Transplant 2010; 29:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/21\">",
"      Lamparter S, Schoppet M, Pankuweit S, Maisch B. Acute parvovirus B19 infection associated with myocarditis in an immunocompetent adult. Hum Pathol 2003; 34:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/22\">",
"      Pankuweit S, Moll R, Baandrup U, et al. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol 2003; 34:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/23\">",
"      Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004; 109:1250.",
"     </a>",
"    </li>",
"    <li>",
"     Schultheiss, H-P. The effect of subcutaneous treatment with interferon-beta-1b over 24 weeks on safety, virus elimination, and clinical outcome in patients with chronic viral cardiomyopathy. Presented November 11th, 2008. AHA Annual Scientific Sessions Late Breaking Clinical Trials III. file://americanheart.mediaroom.com/index.php?s=43&amp;item=590 (Accessed 4-29-09).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/25\">",
"      Baruteau AE, Boimond N, Ramful D. Myocarditis associated with 2009 influenza A (H1N1) virus in children. Cardiol Young 2010; 20:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/26\">",
"      Cassimatis DC, Atwood JE, Engler RM, et al. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004; 43:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/27\">",
"      From the Centers for Disease Control and Prevention. Update: cardiac-related events during the civilian smallpox vaccination program-- United States, 2003. JAMA 2003; 290:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/28\">",
"      Casey CG, Iskander JK, Roper MH, et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 2005; 294:2734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/29\">",
"      Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007; 28:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/30\">",
"      Gerzen P, Granath A, Holmgren B, Zetterquist S. Acute myocarditis. A follow-up study. Br Heart J 1972; 34:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/31\">",
"      Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009; 119:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/32\">",
"      Lambert EC, Menon VA, Wagner HR, Vlad P. Sudden unexpected death from cardiovascular disease in children. A cooperative international study. Am J Cardiol 1974; 34:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/33\">",
"      Stevens PJ, Ground KE. Occurrence and significance of myocarditis in trauma. Aerosp Med 1970; 41:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/34\">",
"      Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/35\">",
"      Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/36\">",
"      Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003; 348:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/37\">",
"      Gauntt CJ. Roles of the humoral response in coxsackievirus B-induced disease. Curr Top Microbiol Immunol 1997; 223:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/38\">",
"      Grist NR, Bell EJ, Assaad F. Enteroviruses in human disease. Prog Med Virol 1978; 24:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/39\">",
"      Lau RC. Coxsackie B virus infections in New Zealand patients with cardiac and non-cardiac diseases. J Med Virol 1983; 11:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/40\">",
"      Chow LH, Beisel KW, McManus BM. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab Invest 1992; 66:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/41\">",
"      Huber SA, Feldman AM, Sartini D. Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-alpha transgenic mice. Circ Res 2006; 99:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/42\">",
"      Godeny EK, Gauntt CJ. Murine natural killer cells limit coxsackievirus B3 replication. J Immunol 1987; 139:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/43\">",
"      Lowenstein CJ, Hill SL, Lafond-Walker A, et al. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest 1996; 97:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/44\">",
"      Horwitz MS, La Cava A, Fine C, et al. Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat Med 2000; 6:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/45\">",
"      Deonarain R, Cerullo D, Fuse K, et al. Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 2004; 110:3540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/46\">",
"      Kandolf R, Canu A, Hofschneider PH. Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon. J Mol Cell Cardiol 1985; 17:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/47\">",
"      Cooper LT Jr, Hare JM, Tazelaar HD, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008; 102:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/48\">",
"      Kodama M, Matsumoto Y, Fujiwara M, et al. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990; 57:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/49\">",
"      Burke AP, Saenger J, Mullick F, Virmani R. Hypersensitivity myocarditis. Arch Pathol Lab Med 1991; 115:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/50\">",
"      Fenoglio JJ Jr, McAllister HA Jr, Mullick FG. Drug related myocarditis. I. Hypersensitivity myocarditis. Hum Pathol 1981; 12:900.",
"     </a>",
"    </li>",
"    <li>",
"     Wu, L, Cooper, LT, Kephart, G, Gleich, GJ. The Eosinophil in Cardiac Disease. In: Cooper L, ed. Myocarditis: From Bench to Bedside, Humana Press, Totowa, NJ. 2002; 437.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/52\">",
"      Taliercio CP, Olney BA, Lie JT. Myocarditis related to drug hypersensitivity. Mayo Clin Proc 1985; 60:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/53\">",
"      Pursnani A, Yee H, Slater W, Sarswat N. Hypersensitivity myocarditis associated with azithromycin exposure. Ann Intern Med 2009; 150:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/54\">",
"      Ben m'rad M, Leclerc-Mercier S, Blanche P, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 2009; 88:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/55\">",
"      Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007; 30:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/56\">",
"      Johnson MR. Eosinophilic myocarditis in the explanted hearts of cardiac transplant recipients: Interesting pathologic finding or pathophysiologic entity of clinical significance? Crit Care Med 2004; 32:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/57\">",
"      Spear GS. Eosinophilic explant carditis with eosinophilia: ?Hypersensitivity to dobutamine infusion. J Heart Lung Transplant 1995; 14:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/58\">",
"      Takkenberg JJ, Czer LS, Fishbein MC, et al. Eosinophilic myocarditis in patients awaiting heart transplantation. Crit Care Med 2004; 32:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/59\">",
"      Gravanis MB, Hertzler GL, Franch RH, et al. Hypersensitivity myocarditis in heart transplant candidates. J Heart Lung Transplant 1991; 10:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/60\">",
"      Hawkins ET, Levine TB, Goss SJ, et al. Hypersensitivity myocarditis in the explanted hearts of transplant recipients. Reappraisal of pathologic criteria and their clinical implications. Pathol Annu 1995; 30 ( Pt 1):287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/61\">",
"      Daniels PR, Berry GJ, Tazelaar HD, Cooper LT. Giant cell myocarditis as a manifestation of drug hypersensitivity. Cardiovasc Pathol 2000; 9:287.",
"     </a>",
"    </li>",
"    <li>",
"     Billingham, M. Morphologic changes in drug-induced heart disease. In: Drug-induced Heart Disease, Bristow, M (Ed), 1980. p.127.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/63\">",
"      Frustaci A, Cuoco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. Circulation 2002; 105:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/64\">",
"      Curione M, Barbato M, De Biase L, et al. Prevalence of coeliac disease in idiopathic dilated cardiomyopathy. Lancet 1999; 354:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/65\">",
"      Polat TB, Urganci N, Yalcin Y, et al. Cardiac functions in children with coeliac disease during follow-up: insights from tissue Doppler imaging. Dig Liver Dis 2008; 40:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/66\">",
"      Chimenti C, Pieroni M, Maseri A, Frustaci A. Histologic findings in patients with clinical and instrumental diagnosis of sporadic arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol 2004; 43:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/67\">",
"      Frustaci A, Verardo R, Caldarulo M, et al. Myocarditis in hypertrophic cardiomyopathy patients presenting acute clinical deterioration. Eur Heart J 2007; 28:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/68\">",
"      Chow LH, Gauntt CJ, McManus BM. Differential effects of myocarditic variants of Coxsackievirus B3 in inbred mice. A pathologic characterization of heart tissue damage. Lab Invest 1991; 64:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/69\">",
"      Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol 2008; 3:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/70\">",
"      Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/71\">",
"      Carson SD, Chapman NN, Tracy SM. Purification of the putative coxsackievirus B receptor from HeLa cells. Biochem Biophys Res Commun 1997; 233:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/72\">",
"      Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 1997; 94:3352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/73\">",
"      Bowles KR, Gibson J, Wu J, et al. Genomic organization and chromosomal localization of the human Coxsackievirus B-adenovirus receptor gene. Hum Genet 1999; 105:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/74\">",
"      Shafren DR, Williams DT, Barry RD. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells. J Virol 1997; 71:9844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/75\">",
"      Clapham PR, Weiss RA. Immunodeficiency viruses. Spoilt for choice of co-receptors. Nature 1997; 388:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/76\">",
"      Martino TA, Petric M, Brown M, et al. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor. Virology 1998; 244:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/77\">",
"      Opavsky MA, Martino T, Rabinovitch M, et al. Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J Clin Invest 2002; 109:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/78\">",
"      Xiong D, Yajima T, Lim BK, et al. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation 2007; 115:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/79\">",
"      Badorff C, Lee GH, Lamphear BJ, et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999; 5:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/80\">",
"      Grady RM, Teng H, Nichol MC, et al. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 1997; 90:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/81\">",
"      Knowlton KU. CVB infection and mechanisms of viral cardiomyopathy. Curr Top Microbiol Immunol 2008; 323:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/82\">",
"      Klingel K, Hohenadl C, Canu A, et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci U S A 1992; 89:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/83\">",
"      Wessely R, Henke A, Zell R, et al. Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes. Circulation 1998; 98:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/84\">",
"      Wessely R, Klingel K, Santana LF, et al. Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J Clin Invest 1998; 102:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/85\">",
"      Martino TA, Liu P, Sole MJ. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ Res 1994; 74:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/86\">",
"      Keeling PJ, Tracy S. Link between enteroviruses and dilated cardiomyopathy: serological and molecular data. Br Heart J 1994; 72:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/87\">",
"      Pauschinger M, Bowles NE, Fuentes-Garcia FJ, et al. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 1999; 99:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/88\">",
"      Akhtar N, Ni J, Stromberg D, et al. Tracheal aspirate as a substrate for polymerase chain reaction detection of viral genome in childhood pneumonia and myocarditis. Circulation 1999; 99:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/89\">",
"      Pauschinger M, Phan MD, Doerner A, et al. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 1999; 99:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/90\">",
"      Why HJ, Meany BT, Richardson PJ, et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994; 89:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/91\">",
"      Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006; 114:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/92\">",
"      Chen F, Shannon K, Ding S, et al. HIV type 1 glycoprotein 120 inhibits cardiac myocyte contraction. AIDS Res Hum Retroviruses 2002; 18:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/93\">",
"      De Castro S, d'Amati G, Gallo P, et al. Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J Am Coll Cardiol 1994; 24:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/94\">",
"      Matsumori A, Ohashi N, Hasegawa K, et al. Hepatitis C virus infection and heart diseases: a multicenter study in Japan. Jpn Circ J 1998; 62:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/95\">",
"      Tsintsof A, Delprado WJ, Keogh AM. Varicella zoster myocarditis progressing to cardiomyopathy and cardiac transplantation. Br Heart J 1993; 70:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/96\">",
"      Figulla HR, Stille-Siegener M, Mall G, et al. Myocardial enterovirus infection with left ventricular dysfunction: a benign disease compared with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1995; 25:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/97\">",
"      Martin AB, Webber S, Fricker FJ, et al. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation 1994; 90:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/98\">",
"      Herskowitz A, Willoughby SB, Baughman KL, et al. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 1992; 116:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/99\">",
"      Herskowitz A, Wu TC, Willoughby SB, et al. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol 1994; 24:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/100\">",
"      Omura T, Yoshiyama M, Hayashi T, et al. Core protein of hepatitis C virus induces cardiomyopathy. Circ Res 2005; 96:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/101\">",
"      K&uuml;hl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with \"idiopathic\" left ventricular dysfunction. Circulation 2005; 111:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/102\">",
"      Tsch&ouml;pe C, Bock CT, Kasner M, et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/103\">",
"      Nakamura H, Yamamura T, Umemoto S, et al. Autoimmune response in chronic ongoing myocarditis demonstrated by heterotopic cardiac transplantation in mice. Circulation 1996; 94:3348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/104\">",
"      Schultheiss HP. The significance of autoantibodies against the ADP/ATP carrier for the pathogenesis of myocarditis and dilated cardiomyopathy--clinical and experimental data. Springer Semin Immunopathol 1989; 11:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/105\">",
"      Caforio AL, Goldman JH, Haven AJ, et al. Circulating cardiac-specific autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. The Myocarditis Treatment Trial Investigators. Eur Heart J 1997; 18:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/106\">",
"      Lauer B, Schannwell M, K&uuml;hl U, et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000; 35:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/107\">",
"      Matsui S, Fu ML, Katsuda S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 1997; 29:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/108\">",
"      Iwata M, Yoshikawa T, Baba A, et al. Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001; 37:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/109\">",
"      M&uuml;ller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/110\">",
"      Wallukat G, M&uuml;ller J, Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002; 347:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/111\">",
"      Maisch B. Autoreactivity to the cardiac myocyte, connective tissue and the extracellular matrix in heart disease and postcardiac injury. Springer Semin Immunopathol 1989; 11:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/112\">",
"      Wolff PG, K&uuml;hl U, Schultheiss HP. Laminin distribution and autoantibodies to laminin in dilated cardiomyopathy and myocarditis. Am Heart J 1989; 117:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/113\">",
"      Caforio AL, Mahon NG, Baig MK, et al. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 2007; 115:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/114\">",
"      Warraich RS, Dunn MJ, Yacoub MH. Subclass specificity of autoantibodies against myosin in patients with idiopathic dilated cardiomyopathy: pro-inflammatory antibodies in DCM patients. Biochem Biophys Res Commun 1999; 259:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/115\">",
"      Warraich RS, Noutsias M, Kazak I, et al. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. Am Heart J 2002; 143:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/116\">",
"      Staudt A, B&ouml;hm M, Knebel F, et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 2002; 106:2448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/117\">",
"      Staudt A, D&ouml;rr M, Staudt Y, et al. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J 2005; 150:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/118\">",
"      Luppi P, Rudert WA, Zanone MM, et al. Idiopathic dilated cardiomyopathy: a superantigen-driven autoimmune disease. Circulation 1998; 98:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/119\">",
"      Opavsky MA, Penninger J, Aitken K, et al. Susceptibility to myocarditis is dependent on the response of alphabeta T lymphocytes to coxsackieviral infection. Circ Res 1999; 85:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/120\">",
"      Henke A, Huber S, Stelzner A, Whitton JL. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol 1995; 69:6720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/121\">",
"      Cruz-Adalia A, Jim&eacute;nez-Borreguero LJ, Ram&iacute;rez-Huesca M, et al. CD69 limits the severity of cardiomyopathy after autoimmune myocarditis. Circulation 2010; 122:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/122\">",
"      Matsumori A. Cytokines in myocarditis and cardiomyopathies. Curr Opin Cardiol 1996; 11:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/123\">",
"      Okura Y, Yamamoto T, Goto S, et al. Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats. J Mol Cell Cardiol 1997; 29:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/124\">",
"      Watanabe K, Nakazawa M, Fuse K, et al. Protection against autoimmune myocarditis by gene transfer of interleukin-10 by electroporation. Circulation 2001; 104:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/125\">",
"      Nishii M, Inomata T, Takehana H, et al. Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol 2004; 44:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/126\">",
"      Bowles NE, Towbin JA. Molecular aspects of myocarditis. Curr Opin Cardiol 1998; 13:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/127\">",
"      Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998; 97:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/128\">",
"      Shioi T, Matsumori A, Sasayama S. Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation 1996; 94:2930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/129\">",
"      Satoh M, Nakamura M, Satoh H, et al. Expression of tumor necrosis factor-alpha--converting enzyme and tumor necrosis factor-alpha in human myocarditis. J Am Coll Cardiol 2000; 36:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/130\">",
"      Caforio AL, Baboonian C, McKenna WJ. Postviral autoimmune heart disease--fact or fiction? Eur Heart J 1997; 18:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/28/22986/abstract/131\">",
"      Caforio AL, Grazzini M, Mann JM, et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992; 85:1734.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4933 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-2DA2A50332-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22986=[""].join("\n");
var outline_f22_28_22986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Viral or \"idiopathic\" myocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Pathogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Incidence and prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Protective effect of initial immune response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Giant cell myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hypersensitivity myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Arrhythmogenic RV cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vaccinia-related myopericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      VIRAL MYOCARDITIS AND DILATED CARDIOMYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Direct viral injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Intracellular events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Persistent viral infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Enterovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Adenovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - HIV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Autoimmune mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Anti-alpha myosin antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Anti-beta-1 adrenoceptor antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Autoreactive T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Role of cytokines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4933\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4933|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/13/2270\" title=\"figure 1\">",
"      Viral infection cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4933|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/10/36014\" title=\"table 1\">",
"      Causes of myocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25226?source=related_link\">",
"      Cardiac involvement in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=related_link\">",
"      Clinical manifestations and diagnosis of Chagas heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=related_link\">",
"      Drug allergy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=related_link\">",
"      Epidemiology and pathogenesis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=related_link\">",
"      Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41927?source=related_link\">",
"      Myopericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=related_link\">",
"      Natural history and therapy of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12872?source=related_link\">",
"      Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22456?source=related_link\">",
"      Non-coronary cardiac manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14615?source=related_link\">",
"      Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/14/15586?source=related_link\">",
"      Patient information: Myocarditis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18809?source=related_link\">",
"      Possibly effective emerging therapies for heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39221?source=related_link\">",
"      Unproven therapies for chronic systolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40057?source=related_link\">",
"      Vaccinia virus as the smallpox vaccine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_28_22987="Pediatric HIV classification - immunologic";
var content_f22_28_22987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric HIV classification system - immunologic categories",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Patient age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &lt;12 months",
"       </td>",
"       <td class=\"subtitle2\">",
"        1-5 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        6-12 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\" colspan=\"3\">",
"        CD4 cells*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune category 1 - no suppression",
"       </td>",
"       <td>",
"        &gt;1500 (&ge;25)",
"       </td>",
"       <td>",
"        &ge;1000 (&ge;25)",
"       </td>",
"       <td>",
"        &ge;500 (&ge;25)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune category 2 - moderate suppression",
"       </td>",
"       <td>",
"        750-1499 (15-24)",
"       </td>",
"       <td>",
"        500-999 (15-24)",
"       </td>",
"       <td>",
"        200-499 (15-24)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune category 3 - severe suppression",
"       </td>",
"       <td>",
"        &lt;750 (&lt;15)",
"       </td>",
"       <td>",
"        &lt;500 (&lt;15)",
"       </td>",
"       <td>",
"        &lt;200 (&lt;15)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * CD4 cells expressed as number of cells/microL (percent of lymphocytes).",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Centers for Disease Control and Prevention. MMWR Recomm Rep 1994; 43(RR-13):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22987=[""].join("\n");
var outline_f22_28_22987=null;
var title_f22_28_22988="Autoantibodies in SLE";
var content_f22_28_22988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical associations of autoantibodies in SLE",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antigen specificity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical associations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence, percent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        dsDNA",
"       </td>",
"       <td>",
"        Marker for active disease, titers fluctuates with disease activity, correlates best with renal disease",
"       </td>",
"       <td>",
"        40-60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ssDNA",
"       </td>",
"       <td>",
"        Nonspecific, no clinical utility",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ro/SSA",
"       </td>",
"       <td>",
"        Subacute cutaneous lupus (75 percent), photosensitivity, neonatal lupus, complement deficiencies",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RNP (U1-RNP)",
"       </td>",
"       <td>",
"        SLE generally in conjunction with Sm; in MCTD, required for diagnosis",
"       </td>",
"       <td>",
"        30-40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        La/SSB",
"       </td>",
"       <td>",
"        <p>",
"         With La, low prevalence of renal disease",
"        </p>",
"        <p>",
"         Neonatal lupus (75 percent)",
"        </p>",
"       </td>",
"       <td>",
"        10-15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sm",
"       </td>",
"       <td>",
"        <p>",
"         Marker for disease, not generally useful in management;",
"        </p>",
"        <p>",
"         May be associated with CNS disease",
"        </p>",
"       </td>",
"       <td>",
"        About 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phospholipids",
"       </td>",
"       <td>",
"        Hypercoagulable state in some patients. No clinical significance in others. Thrombocytopenia, later trimester abortions",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histones",
"       </td>",
"       <td>",
"        &gt;95 percent in drug-related lupus. Also present in RA, SLE, reported in",
"systemic sclerosis with pulmonary fibrosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ribosomal P",
"       </td>",
"       <td>",
"        Initially associated with",
"psychosis in SLE, more recently with depression",
"       </td>",
"       <td>",
"        10-40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KU",
"       </td>",
"       <td>",
"        <p>",
"         SLE, MCTD (European, American population)",
"        </p>",
"        <br/>",
"        <p>",
"         Scleroderma/myositis overlap (Japanese population)",
"        </p>",
"       </td>",
"       <td>",
"        &le;19 , &le;39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCNA",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Rates vary depending on technique used.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22988=[""].join("\n");
var outline_f22_28_22988=null;
var title_f22_28_22989="Etiology fetal death";
var content_f22_28_22989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of fetal death",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Perinatal infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Group B Streptococcus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        E coli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Listeria monocytogenes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Spirochaetal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Parvovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Herpes simplex virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rubella virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protozoal, eg Toxoplasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other specified organism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypertension or preeclampsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antepartum hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placental abruption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placenta previa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasa previa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Maternal conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Termination of pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes/gestational diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Maternal injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Accidental",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Non-accidental",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obstetric cholestasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Perinatal conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Twin-twin transfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetomaternal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antepartum cord complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alloimmune disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonimmune fetal hydrops",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypoxic peripartum death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        With intrapartum complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Uterine rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cord prolapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Shoulder dystocia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence of non-reassuring fetal status in a normally grown infant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No intrapartum complications and no evidence of non-reassuring fetal status.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fetal growth restriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unspecified or not known whether placenta examined",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Spontaneous preterm birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intact membranes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ruptured membranes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Unexplained antepartum death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        With evidence of reduced vascular perfusion on Doppler studies and/or placental histopathology (eg significant infarction, acute atherosis, maternal and/or fetal vascular thrombosis or maternal floor infarction)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        With chronic villitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No placental pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other specified placental pathology",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Chan, A, King, JF, Flenady, V, Haslam, RH, Tudehope DI. Classification of perinatal deaths: development of the Australian and New Zealand classifications. J Paediatr Child Health 2004; 40:340.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22989=[""].join("\n");
var outline_f22_28_22989=null;
var title_f22_28_22990="Inflamed ingrown toenail";
var content_f22_28_22990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ingrown toenail postoperatively",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Significant erythema is evident; the involved nail wedge was removed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22990=[""].join("\n");
var outline_f22_28_22990=null;
var title_f22_28_22991="Proximal phalanx oblique fracture AP xray";
var content_f22_28_22991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oblique fracture of the proximal phalanx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 534px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph shows an oblique fracture of the proximal phalanx (white arrow). Oblique fractures may be stable if the periosteal sleeve is intact.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_28_22991=[""].join("\n");
var outline_f22_28_22991=null;
